Go to MDedge.com/CHESTPhysician for the latest news on coronavirus and long COVID.

CARDIOLOGY What's the best anticoagulant in terms of bleeding risk? // 13

CORONAVIRUS

Millions have long COVID, and more cases are expected // 13

SLEEP MEDICINE

Race and gender: Tailoring sleep treatments // 21

VOL. 17 • NO. 12 • DECEMBER 2022

Sector CHEST Physician[®]



Pulmonologist consult at COPD admission reduces readmissions

Rosemont, IL 60018 10255 W Higgins Road, Suite 280

CHEST PHYSICIAN

BY TED BOSWORTH

AT CHEST 2022 NASHVILLE, TENN. – If a pulmonologist becomes involved early in the care of patients admitted to the hospital for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), the rate of readmission is reduced substantially relative to no pulmonologist involvement, according to a retrospective cohort review presented at the annual meeting of the American College of Chest Physicians (CHEST).

"When stratified by severity of COPD at the time of admission, the difference in the readmission rate was even greater," reported Nakisa Hekmat-Joo, MD, a third-year resident at Staten Island University Hospital, New York.

Just as protocols have been developed for prompt initiation of antibiotics in patients with septicemia or prompt revascularization in patients with ST-elevation myocardial infarction (STEMI), Dr. Hekmat-Joo said the data from this study warrant a larger trial to evaluate whether an AECOPD admission protocol is warranted to improve outcomes and lower costs.

In this study, all AECOPD admissions were included from a recent 2-year period at two Staten Island hospitals. Of these, 198 patients received a pulmonologist consult within 24 hours. The remaining 92 patients were not evaluated by pulmonologists but were admitted and then managed by residents, internists, or others. **CONSULT** // continued on page

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

Wake-up call on sleep and cardiovascular health

BY MARILYNN LARKIN

ardiovascular health (CVH) scores that include sleep predicted CV disease risk among older U.S. adults, supporting the American Heart Association's recent inclusion of sleep in its own checklist.

Sleep duration is now considered "an essential component for ideal heart and brain health," according to the AHA's updated checklist, now called Life's Essential 8. "Our study is the first to show that sleep metrics add independent predictive value for cardiovascular disease (CVD) events over and above the original seven CVH metrics, providing support for updating the guidelines from Life's Simple 7 (LS7) to Life's Essential 8," lead author Nour Makarem, PhD, of the Mailman School of Public Health at Columbia University Irving Medical Center, New York, said in an interview.

For the study, her team compared four versions of LS7 checklists that included sleep in relation to CVD risk.

"CVH scores that included sleep duration alone as a measure of overall sleep health, as well as scores that included multiple dimensions of **SLEEP AND CVH** // continued on page 6

INSIDE HIGHLIGHT



NEWS FROM CHEST Critical Care Commentary


Managing workforce issues in the COVID-19 era: A call to action. 8






SUBSCRIBE NOW

BATTLE TESTED IN EOS DISEASE



With proven results across **4 indications** our track record stands out



NUCALA is for the:

- add-on maintenance treatment of patients 6+ with SEA. Not for acute bronchospasm or status asthmaticus.
- add-on maintenance treatment of CRSwNP in patients 18+ with inadequate response to nasal corticosteroids.
- treatment of adult patients with EGPA.
- treatment of patients aged 12+ with HES for ≥6 months without an identifiable non-hematologic secondary cause.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

Visit NucalaBattleTested.com to learn more





Nucala (mepolizumab) Injection 100 mg/mL

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). If a hypersensitivity reaction occurs, discontinue NUCALA.

Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

ADVERSE REACTIONS

Most common adverse reactions (≥5%) in patients receiving NUCALA:

- Severe asthma trials: headache, injection site reaction, back pain, fatigue
- CRSwNP trial: oropharyngeal pain, arthralgia
- EGPA and HES trials (300 mg of NUCALA): no additional adverse reactions were identified to those reported in severe asthma clinical trials

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

USE IN SPECIFIC POPULATIONS

A pregnancy exposure registry monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/asthma.

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

Please see Brief Summary of Prescribing Information for NUCALA on the following pages. Trademarks are owned by or licensed to the GSK group of companies.



©2022 GSK or licensor. MPLJRNA220004 August 2022 Produced in USA.

NUCALA (mepolizumab) for injection, for subcutaneous use

NUCALA (mepolizumab) injection, for subcutaneous use The following is a brief summary only; see full prescribing information for complete product information.

1 INDICATIONS AND USAGE

1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations (8.4) and Clinical Studies (14.1) of full prescribing information]. Limitations of Use

NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

1.2 Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

1.3 Eosinophilic Granulomatosis with Polyangiitis

NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

1.4 Hypereosinophilic Syndrome

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for >6 months without an identifiable non-hematologic secondary cause.

4 CONTRAINDICATIONS

NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see Warnings and Precautions (5.1) and Description (11) of full prescribing information].

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances can have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, NUCALA should be discontinued [see Contraindications (4)].

5.2 Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms or acute exacerbations. Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

5.3 Opportunistic Infections: Herpes Zoster

Herpes zoster has occurred in subjects receiving NUCALA 100 mg in controlled clinical trials [see Adverse Reactions (6.1)1. Consider vaccination if medically appropriate.

5.4 Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of therapy with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

5.5 Parasitic (Helminth) Infection

Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient's response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.

6 ADVERSE REACTIONS

- Hypersensitivity reactions are described in greater detail in other sections:
 Hypersensitivity reactions [see Warnings and Precautions (5.1)]
 Opportunistic infections: herpes zoster [see Warnings and Precautions (5.3)]
 Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the

clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience in Severe Asthma Adult and Adolescent Patients Aged 12 Years and Older

A total of 1,327 patients with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks' duration (Trial 1, NCT01000506; Trial 2, NCT01691521; and Trial 3, NCT01691508). Of these, 1,192 had a history of 2 or more exacerbations in the year prior to enrollment despite regular use of high-dose ICS plus additional controller(s) (Trials 1 and 2), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control (Trial 3). All patients had markers of eosinophilic airway inflammation [see Clinical Studies (14.1) of full prescribing information]. Of the patients enrolled, 59% were female, 85% were White, and ages ranged from 12 to 82 years. Mepolizumab was administered subcutaneously or intravenously once every 4 weeks; 263 patients received NUCALA (mepolizumab 100 mg subcutaneous) for at least 24 weeks. Serious adverse events that occurred in more than 1 patient and in a greater percentage of patients receiving NUCALA 100 mg (n = 263) than placebo (n = 257) included 1 event, herpes zoster (2 patients vs. 0 patients, respectively). Approximately 2% of patients receiving NUCALA 100 mg withdrew from clinical trials due to adverse events compared with 3% of patients receiving placebo. The incidence of adverse reactions in the first 24 weeks of treatment in the 2 confirmatory efficacy and safety

trials (Trials 2 and 3) with NUCALA 100 mg is shown in Table 1.

Table 1. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with Severe Asthma (Trials 2 and 3)

Adverse Reaction	NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 263) %	Placebo (n = 257) %
Headache	19	18
Injection site reaction	8	3
Back pain	5	4
Fatigue	5	4
Influenza	3	2
Urinary tract infection	3	2
Abdominal pain upper	3	2
Pruritus	3	2
Eczema	3	<1
Muscle spasms	3	<1

52-Week Trial: Adverse reactions from Trial 1 with 52 weeks of treatment with mepolizumab 75 mg intravenous (IV) (n = 153) or placebo (n = 155) and with $\ge 3\%$ incidence and more common than placebo and not shown in Table 1 were: abdominal pain, allergic rhinitis, asthenia, bronchitis, cystitis, dizziness, dyspnea, ear infection, gastroenteritis, lower respiratory tract infection, musculoskeletal pain, nasal congestion, nasopharyngitis, nausea, pharvnoitis, pyrexia, rash, toothache, viral infection, viral respiratory tract infection, and vomiting. In addition, 3 cases of herpes zoster occurred in patients receiving mepolizumab 75 mg IV compared with 2 patients in the placebo group.

Systemic Reactions, including Hypersensitivity Reactions: In Trials 1, 2, and 3 described above, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100 mg and 5% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients in the group receiving NUCALA 100 mg and 2% of patients in the placebo group. The most commonly reported manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving NUCALA 100 mg included rash, pruritus, headache, and myalgia. Systemic non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100 mg and 3% of patients in the placebo group. The most commonly reported manifestations of systemic non-allergic reactions reported in the group receiving NUCALA 100 mg included rash, flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 100 mg (5/7) were experienced on the day of dosing.

Injection Site Reactions: Injection site reactions (e.g., pain, erythema, swelling, itching, burning sensation) occurred at a rate of 8% in patients receiving NUCALA 100 mg compared with 3% in patients receiving placebo. *Long-term Safety:* Nine hundred ninety-eight patients received NUCALA 100 mg in ongoing open-label extension studies, during which additional cases of herpes zoster were reported. The overall adverse event profile has been similar to the asthma trials described above.

Pediatric Patients Aged 6 to 11 Years The safety data for NUCALA is based upon 1 open-label clinical trial that enrolled 36 patients with severe asthma aged 6 to 11 years. Patients received 40 mg (for those weighing <40 kg) or 100 mg (for those weighing >40 kg) of NUCALA administered subcutaneously once every 4 weeks. Patients received NUCALA for 12 weeks (initial short phase). After a treatment interruption of 8 weeks, 30 patients received NUCALA for a further 52 weeks (long phase). The adverse reaction profile for patients aged 6 to 11 years was similar to that observed in patients aged 12 vears and older

6.2 Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps

6.2 Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps A total of 407 patients with CRSwNP were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received NUCALA 100 mg or placebo subcutaneously once every 4 weeks. Patients had recurrent CRSwNP with a history of prior surgery and were on nasal corticosteroids for at least 8 weeks prior to screening *[see Clinical Studies (14.2) of full prescribing information]*. Of the patients enrolled, 35% were female, 93% were White, and ages ranged from 18 to 82 years. Approximately 2% of patients receiving NUCALA 100 mg withdrew from study treatment due to adverse events compared with 2% of patients receiving placebo. Table 2 summarizes adverse reactions that occurred in ≥3% of NUCALA-treated patients and more frequently than in patients treated with placebo. patients treated with placebo in the CRSwNP trial.

Table 2. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with CRSwNF

Adverse Reaction	NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 206) %	Placebo (n = 201) %
Oropharyngeal pain	8	5
Arthralgia	6	2
Abdominal Pain Upper	3	2
Diarrhea	3	2
Pyrexia	3	2
Nasal dryness	3	<1
Rash	3	<1

CRSwNP = Chronic Rhinosinusitis with Nasal Polyps.

Systemic Reactions, including Hypersensitivity Reactions other) reactions was <1% in the group receiving NUCALA 100 mg and <1% in the placebo group. Systemic allergic (type I hypersensitivity) reactions were reported by <1% of patients in the group receiving NUCALA 100 mg and no patients in the placebo group. The manifestations of systemic allergic (type I hypersensitivity) reactions included urticaria, erythema, and rash and 1 of the 3 reactions occurred on the day of dosing. Other systemic reactions were reported by no patients in the group receiving NUCALA 100 mg and <1% of patients in the placebo group.

Injection Site Reactions Injection site reactions (e.g., erythema, pruritus) occurred at a rate of 2% in patients receiving NUCALA 100 mg compared with <1% in patients receiving placebo.

6.3 Clinical Trials Experience in Eosinophilic Granulomatosis with Polyangiitis

A total of 136 patients with EGPA were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients enrolled had a diagnosis of EGPA for at least 6 months prior to enrollment with a history of relapsing or refractory disease and were on a stable dosage of oral prednisolone or prednisone of greater than or equal to 7.5 mg/ day (but not greater than 50 mg/day) for at least 4 weeks prior to enrollment [see Clinical Studies (14.3) of full prescribing information]. Of the patients enrolled, 59% were female, 92% were White, and ages ranged from 20 to 71 years. No additional adverse reactions were identified to those reported in the severe asthma trials. Systemic Reactions, including Hypersensitivity Reactions

Systemic Reactions, including hypersensitivity reactions In the 52-week trial, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 6% in the group receiving 300 mg of NUCALA and 1% in the placebo group. Systemic allergic/ hypersensitivity reactions were reported by 4% of patients in the group receiving 300 mg of NUCALA and 1% of patients in the placebo group. The manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving 300 mg of NUCALA included rash, pruritus, flushing, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, and stridor. Systemic non-allergic reactions were reported by 1 (1%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of systemic non-allergic reactions reported in the group receiving 300 mg of NUCALA was angioedema. Half of the systemic reactions in patients receiving 300 mg of NUCALA (2/4) were experienced on the day of dosing.

Injection Site Reactions

Injection site reactions (e.g., pain, erythema, swelling) occurred at a rate of 15% in patients receiving 300 mg of NUCALA compared with 13% in patients receiving placebo.

6.4 Clinical Trials Experience in Hypereosinophilic Syndrome

A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo-controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1-PDGFRa kinase-positive HES were excluded from the trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients must have been on a stable dose of background HES therapy for the 4 weeks prior to randomization [see Clinical Studies (14.4) of full prescribing information]. Of the patients enrolled, 53% were female, 93% were White, and ages ranged from 12 to 82 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the trial, no systemic allergic (type I hypersensitivity) reactions were reported. Other systemic reactions were reported by 1 (2%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of other systemic reaction was multifocal skin reaction experienced on the day of dosing. (continued on next page)

BRIEF SUMMARY

6 ADVERSE REACTIONS (cont'd)

Injection Site Reactions

Injection site reactions (e.g., burning, itching) occurred at a rate of 7% in patients receiving 300 mg of NUCALA compared with 4% in patients receiving placebo.

6.5 Immunogenicity

In adult and adolescent patients with severe asthma receiving NUCALA 100 mg, 15/260 (6%) had detectable anti-mepolizumab antibodies. Neutralizing antibodies were detected in 1 patient with asthma receiving NUCALA 100 mg. Anti-mepolizumab antibodies slightly increased (approximately 20%) the clearance of mepolizumab. There was no evidence of a correlation between anti-mepolizumab antibody titers and change in eosinophil level. The clinical relevance of the presence of anti-mepolizumab antibodies is not known. In the clinical trial of children aged 6 to 11 years with severe asthma receiving NUCALA 40 or 100 mg, 2/35 (6%) had detectable antimepolizumab antibodies during the initial short phase of the trial. No children had detectable anti-mepolizumab antibodies during the long phase of the trial.

In patients with CRSwNP receiving NUCALA 100 mg, 6/196 (3%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with CRSwNP. In patients with EGPA receiving 300 mg of NUCALA, 1/68 (<2%) had detectable anti-mepolizumab antibodies.

No neutralizing antibodies were detected in any patients with EGPA. In adult and adolescent patients with HES receiving 300 mg of NUCALA, 1/53 (2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with HES.

The reported frequency of anti-mepolizumab antibodies may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentration. The data reflect the percentage of patients whose test results were positive for antibodies to mepolizumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.

6.6 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of NUCALA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to NUCALA or a combination of these factors. Immune System Disorders

Hypersensitivity reactions, including anaphylaxis.

7 DRUG INTERACTIONS

Formal drug interaction trials have not been performed with NUCALA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. Healthcare providers can enroll patients or encourage patients to enroll themselves by calling 1-877-311-8972 or visiting www.mothertobaby.org/asthma.

The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. In a prenatal and postnatal development study conducted in cynomolgus monkeys, there was no evidence of fetal harm with IV administration of mepolizumab throughout pregnancy at doses that produced exposures up to approximately 9 times the exposure at the maximum recommended human dose (MRHD) of 300 mg subcutaneous (*see Data*). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control Data

Animal Data: In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation Days 20 to 140 at doses that produced exposures up to approximately 9 times that achieved with the MRHD (on an AUC basis with maternal IV doses up to 100 mg/kg once every 4 weeks). Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth. Examinations for internal or skeletal malformations were not performed. Mepolizumab crossed the placenta in cynomolgus monkeys. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers up to Day 178 postpartum. Levels of mepolizumab in milk were ≤0.5% of maternal serum concentration.

In a fertility, early embryonic, and embryofetal development study, pregnant CD-1 mice received an analogous antibody, which inhibits the activity of murine interleukin-5 (IL-5), at an IV dose of 50 mg/kg once per week throughout gestation. The analogous antibody was not teratogenic in mice. Embryofetal development of IL-5-deficient mice has been reported to be generally unaffected relative to wild-type mice.

8.2 Lactation

Risk Summarv

There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production. However, mepolizumab is a humanized monoclonal antibody (lgG1 kappa), and immunoglobulin G (lgG) is present in human milk in small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy [see Use in Specific Populations (8.1)]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or from the underlying maternal condition.

8.4 Pediatric Use

Severe Asthma

The safety and efficacy of NUCALA for severe asthma, and with an eosinophilic phenotype, have been established in pediatric patients aged 6 years and older. Use of NUCALA in adolescents aged 12 to 17 years is supported by evidence from adequate and well-controlled

trials in adults and adolescents. A total of 28 adolescents aged 12 to 17 years with severe asthma were enrolled in the Phase 3 asthma trials. Of these, 25 were enrolled in the 32-week exacerbation trial (Trial 2, NCT01691521) and had a mean age of 14.8 years. Patients had a history of 2 or more exacerbations in the previous yea despite regular use of medium- or high-dose ICS plus additional controller(s) with or without OCS and had blood eosinophils of \geq 150 cells/mcL at screening or \geq 300 cells/mcL within 12 months prior to enrollment. *[See Clinical* Studies (14.1) of full prescribing information.) Patients had a reduction in the rate of exacerbations that trended in favor of NUCALA. Of the 19 adolescents who received NUCALA, 9 received 100 mg and the mean apparent clearance in these patients was 35% less than that of adults. The safety profile observed in adolescents was generally similar to that of the overall population in the Phase 3 studies *[see Adverse Reactions (6.1)]*. Use of NUCALA in pediatric patients aged 6 to 11 years with severe asthma, and with an eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in children aged 6 to 11 years. A single, open-label clinical trial (NCT02377427) was conducted in 36 children aged 6 to 11 years (mean age: 8.6 years, 31% female) with severe asthma. Enrollment criteria were the same as for adolescents in the 32-week exacerbation trial (Trial 2). Based upon the pharmacokinetic data from this trial, a dose of 40 mg subcutaneous every 4 weeks was determined to have similar exposure to adults and adolescents administered a dose of 100 mg SC [see Clinical Pharmacology (12.3) of full prescribing information].

The effectiveness of NUCALA in pediatric patients aged 6 to 11 years is extrapolated from efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar drug exposure levels for 40 mg administered subcutaneously every 4 weeks in children aged 6 to 11 years compared with adults and adolescents *[see Clinical Pharmacology (12.3) of full prescribing information]*. The safety profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were similar to that seen in adults and adolescents [see Adverse Reactions (6.1), Clinical Pharmacology (12.2) of full prescribing information]. The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma have not been established.

<u>Chronic Rhinosinusitis with Nasal Polyps</u> The safety and effectiveness in patients aged younger than 18 years with CRSwNP have not been established. Eosinophilic Granulomatosis with Polyangiitis

The safety and effectiveness in patients aged younger than 18 years with EGPA have not been established. Hypereosinophilic Syndrome

The safety and effectiveness of NUCALA for HES have been established in adolescent patients aged 12 years and older. The safety and effectiveness in pediatric patients aged younger than 12 years with HES have not been established. Use of NUCALA for this indication is supported by evidence from an adequate and well-controlled study (NCT02836496) in adults and adolescents and an open-label extension study (NCT03306043). One adolescent received NUCALA during the controlled study and this patient and an additional 3 adolescents received NUCALA during the open-label extension study [see Clinical Studies (1.4) of full prescribing information]. The 1 adolescent treated with NUCALA in the 32-week trial did not have a HES flare or an adverse event reported. All adolescents received 300 mg of NUCALA for 20 weeks in the open-label extension.

8.5 Geriatric Use

Clinical trials of NUCALA did not include sufficient numbers of patients aged 65 years and older that received NUCALA (n = 79) to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Based on available data, no adjustment of the dosage of NUCALA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

10 OVERDOSAGE

There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

13 NONCLINICAL TOXICOLOGY

13.1 CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

Long-term animal studies have not been performed to evaluate the carcinogenic potential of mepolizumab. Published literature using animal models suggests that IL-5 and eosinophils are part of an early inflammatory reaction at the site of tumorigenesis and can promote tumor rejection. However, other reports indicate that eosinophil infiltration into tumors can promote tumor growth. Therefore, the malignancy risk in humans from an antibody to IL-5 such as mepolizumab is unknown.

Male and female fertility were unaffected based upon no adverse histopathological findings in the reproductive organs from cynomolgus monkeys receiving mepolizumab for 6 months at IV dosages up to 100 mg/kg once every 4 weeks (approximately 20 times the MRHD of 300 mg on an AUC basis). Mating and reproductive performance were unaffected in male and female CD-1 mice receiving an analogous antibody, which inhibits the activity of murine IL-5, at an IV dosage of 50 mg/kg once per week.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hypersensitivity Reactions

Inform patients that hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. Instruct patients to contact their physicians if such reactions occur.

Not for Acute Symptoms or Deteriorating Disease

Inform patients that NUCALA does not treat acute asthma symptoms or acute exacerbations. Inform patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA. **Opportunistic Infections: Herpes Zoster**

appropriate, inform patients that herpes zoster infections have occurred in patients receiving NUCALA and where medically appropriate, inform patients that vaccination should be considered.

Reduction of Corticosteroid Dosage

Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Pregnancy Exposure Registry

Inform women there is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy and that they can enroll in the Pregnancy Exposure Registry by calling 1-877-311-8972 or by visiting www.mothertobaby.org/asthma [see Use in Specific Populations (8.1)].

Trademarks are owned by or licensed to the GSK group of companies.

Manufactured by GlaxoSmithKline LLC Philadelphia, PA 19112 U.S. License Number 1727

Distributed by



GlaxoSmithKline Research Triangle Park, NC 27709

©2022 GSK group of companies or its licensor.

Revised: 1/2022

©2022 GSK or licensor. MPLJRNA220004 August 2022 Produced in USA.

NCL:9BRS

Sleep and CVH // continued from page 1

sleep health (that is, sleep duration, efficiency, and regularity; daytime sleepiness; and sleep disorders), were both predictive of future CVD," she said.

Study participants scoring in the highest tertile of the CVH checklists that included sleep had up to a 47% lower CVD risk.

Sleeping 7 hours or more but less than 9 hours nightly was considered "ideal," according to the study, published online in the Journal of the American Heart Association (2022. doi: 10.1161/JAHA.122.025252).

Lower the odds

Dr. Makarem and colleagues analyzed data from participants in the Multi-Ethnic Study of Atherosclerosis (MESA) sleep study using overnight polysomnography, 7-day wrist actigraphy, validated questionnaires, and outcomes. They used the data to evaluate the four iterations of an expanded LS7 score:

- Score 1 included sleep duration;
- Score 2 included sleep characteristics linked to CVD in the literature (sleep duration, insomnia, daytime sleepiness, and obstructive sleep apnea [OSA]);
- Score 3 included sleep characteristics associated with CVD in MESA (sleep duration and efficiency, daytime sleepiness, and OSA); and
- Score 4, also based on CVD in MESA, included sleep regularity. Among 1,920 participants (mean

age 69 years; 54% women; 40%, White individuals), the mean LS7 score was 7.3, and the means of the alternate CVH scores that included sleep ranged from 7.4 to 7.8 (scores range from 0 to 14, with higher scores indicating better CVH).

On actigraphy, 63% of participants slept less than 7 hours; 30% slept less than 6 hours; 39% had high night-to-night variability in sleep duration; and 25% had high variability in sleep-onset timing.

Overall, 10% had sleep efficiency less than 85%; 14% had excessive daytime sleepiness; 36% had high insomnia symptoms; and 47% had

Erratum

Mary Jo S. Farmer, MD, PhD, FCCP, should be listed as the first author in the Networks article "Pulmonary Vascular Disease Section – Key Messages from the 2022 ESC/ ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension" (page 19, November issue). moderate to severe OSA. Shortduration sleepers also had a higher prevalence of overweight/obesity, diabetes, and hypertension and had lower mean LS7 scores. And during a mean follow-up of 4.4 years, 95 prevalent CVD events and 93 incident cases occurred.

Higher scores on all four expanded versions were related to lower odds of having CVD. Participants in the highest versus the lowest tertile of the LS7 score had 75% lower CVD odds (odds ratio, 0.25). Similarly, those in the highest vs. the lowest tertile of CVH scores 1 and 2 had 71% and 80% lower odds of prevalent CVD (OR, 0.29; and OR, 0.20), respectively.

Participants in the highest vs. lowest tertile of the LS7 score and all CVH scores had up to 80% lower odds of prevalent CVD; those in the highest vs. lowest tertile of CVH score 1, which included sleep duration, and CVH score 4, which included multidimensional sleep health, had 43% and 47% lower incident CVD risk (hazard ratios, 0.57 and 0.53), respectively. The LS7 score alone was not associated with CVD incidence (HR, 0.62).

Sleep 'devalued'

"The sleep field has been fighting to get more sleep education into medical education for decades," t Michael A. Grandner, PhD, Director of the Sleep & Health Research Program and of the Behavioral Sleep Medicine Clinic at the University of Arizona College of Medicine, Tucson, said in an interview. "To my knowledge, there still is not a lot of attention given to it, partly because the culture in medical school and among residents is one of not sleeping," said Dr. Grandner, who was not involved in the study. "The culture among physicians is 'Who needs sleep?'

"Sleep made it to the checklist because it is a biological requirement for human life," he noted. "We sleep for the same reason we breathe and drink. It's an imperative. Yet we live in a society that devalues sleep."

Clinicians should ask all patients about how they're sleeping at every visit, Dr. Grandner said. "It's now part of the official definition of heart health. Just like you would be remiss if you didn't ask about smoking or test blood pressure, you'd be missing something important by not asking about sleep – something that has similar billing to diet, exercise, blood pressure, and all the other 'essentials."

No conflicts were declared.

NEWS FROM CHEST // 8

PULMONARY PERSPECTIVES® // 12

CHEST PHYSICIAN IS ONLINE CHEST Physician is available at

chestphysician.org.



Angel Coz, MD, FCCP, is Editor in Chief of CHEST Physician.

SCHEST Physician[®]

AMERICAN COLLEGE OF CHEST PHYSICIANS (CHEST) EDITOR IN CHIEF

Angel Coz, MD, FCCP PRESIDENT David Schulman, MD, MPH, FCCP **EXECUTIVE VICE PRESIDENT & CEO** Robert Musacchio, PhD **PUBLISHER, CHEST** Nicki Augustyn, CAE DIRECTOR, COMMUNICATIONS AND CREATIVE STRATEGIES Susan Rice MANAGER, EDITORIAL RESOURCES Pamela L. Goorsky **MANAGING EDITOR, NEWS CHANNELS** Danielle Leber SECTION EDITORS Aaron B. Holley, MD, FCCP Pulmonary Perspectives Daniel R. Ouellette, MD, FCCP Critical Care Commentary Michelle Cao, DO, FCCP **Sleep Strategies**

Editorial Board

Humayun Anjum, MD, FCCP A. Christine Argento, MD, FCCP Abbie Begnaud, MD, FCCP David L. Bowton, MD, FCCP Mary Cataletto, MD, FCCP Carolyn D'Ambrosio, MD, FCCP Mary Jo S. Farmer, MD, PhD, FCCP Sachin Gupta, MD, FCCP Loren Harris, MD, FCCP Jonathan Ludmir, MD Diego Maselli, MD, FCCP Mangala Narasimhan, DO, FCCP Brandon M. Seay, MD Shyam Subramanian, MD, FCCP Sai Venkateshlah, MD, FCCP Corinne Young, MSN, FNP-C, FCCP

E-mail: chestphysiciannews@chestnet.org ©Copyright 2022, by the American College of Chest Physicians



FRONTLINE MEDICAL COMMUNICATIONS SOCIETY PARTNERS

EDITORIAL DIRECTOR Kathy Scarbeck, MA EDITOR Mark S. Lesney, PhD CREATIVE DIRECTOR Louise A. Koenig

DIRECTOR, PRODUCTION/MANUFACTURING Rebecca Slebodnik

DIRECTOR BUSINESS DEVELOPMENT Anne Gilhool, 914-916-2487 agilhool@mdedge.com **CHEST PHYSICIAN**, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to CHEST members. Content for **CHEST PHYSICIAN** is provided by Frontline Medical Communications Inc. Content for News From Chest is provided by the American College of Chest Physicians.

The statements and opinions expressed in **CHEST Physician** do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

POSTMASTER: Send change of address (with old mailing label) to CHEST PHYSICIAN, Subscription Services, 10255 W Higgins Road, Suite 280, Rosemont, IL 60018-9914.

RECIPIENT: To change your address, contact Subscription Services at 1-800-430-5450. For paid subscriptions, single issue purchases, and missing issue claims, call Customer Service at 1-833-836-2705 or e-mail custsvc.chph@fulcoinc.com

CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 283-299 Market Street (2 Gateway Building), 4th Floor, Newark, NJ 07102. Subscription price is \$244.00 per year. Phone 973-206-3434, fax 973-206-9378.

EDITORIAL OFFICES 2275 Research Blvd, Suite 400, Rockville, MD 20850, 973-206-3434, fax 240-221-2548

FRONTLINE MEDICAL COMMUNICATIONS

Corporate

- VP, SALES Mike Guire
- VP, SALES LEAD Dino Marsella

VP, MEMBER MARKETING Amy Pfeiffer

VP, PARTNERSHIPS, PRODUCTS & STRATEGY: U.S. AND GLOBAL Amy Nadel

VP, SALES, STRATEGY & PARTNERSHIPS JoAnn Wahl

DIRECTOR, CIRCULATION Jared Sonners **EXECUTIVE EDITOR** Patrick Finnegan

VP, PROPRIETARY CONFERENCES, MEDSCAPELIVE David J. Small, MBA

Consult // continued from page 1

The primary outcome was length of stay (LOS). Although the slightly lower LOS in the pulmonologist-treated group did not approach significance (4.16 vs. 4.21 days; P = .88), the readmission rate at 90 days, which was a secondary outcome, was reduced by almost half (30.1% vs. 57.6%; P < .0001).

At admission, there was no significant difference between those receiving a pulmonologist consult and those who did not. The average O_2 saturation was lower in the group seen by a pulmonologist (93% vs. 95.4%; P < .0001), but the most striking difference was the low relative readmission rate, which remained significant after controlling for severity and for pulmonary function.

"When we stratified patients for baseline severity, the advantage of a pulmonologist consult was even greater for those with the most severe disease," Dr. Hekmat-Joo said. Among those with the greatest severity, the 90-day readmission rate was nearly three times greater in the absence of a pulmonologist consult (72% vs. 28%).

Although the comparison of outcomes for those receiving a pulmonologist consult vs. those who did not was adjusted for COPD severity, the potential for pulmonologist consults to be ordered for those patients who looked the sickest would have likely worked against the study result.

"We speculate that pulmonologists were more likely than internists to treat beyond standard guidelines, particularly in the event of greater severity," Dr. Hekmat-Joo explained.

These steps might include earlier use of

noninvasive positive pressure ventilation or earlier initiation of rehabilitation strategies.

There were several signals that a pulmonologist consult led to more rigorous care.

"The average time to follow-up after hospitalization was 23 days for the pulmonologist group and 66 days for the nonpulmonologist group," said Dr. Hekmat-Joo, noting this difference was highly significant (P = .0052).

Based on these results, Dr. Hekmat-Joo and her co-investigators are now working on a protocol for COPD admissions that involves a pulmonologist consult within 24 hours of admission. She hopes to test this protocol in a prospective trial.

"COPD remains a major cause of death and consumes enormous health care resources. About 30% of the cost of COPD care is due to readmissions," she said, noting that readmissions adversely impact quality of life.

Asked if there was sufficient staff at her institution to allow for a pulmonologist consult with every COPD admission, Dr. Hekmat-Joo acknowledged that this has to be demonstrated, but compelling evidence of a benefit might prompt a redistribution of resources.

"If we can show that readmissions are substantially reduced, adding staff to perform these consults would be a good investment," said Dr. Hekmat-Joo, indicating that improved outcomes could also attract the attention of third-party payers and those tracking quality-of-care metrics.

There is a strong rationale for a randomized prospective trial to confirm the value of a pulmonologist consultation following admission for an acute exacerbation of COPD, according to Nicola A. Hanania, MD, FCCP, director, Airways Clinical Research Center, Baylor College of Medicine, Houston.

The potential for benefit as seen in this retrospective study is a rational expectation and might be related to more appropriate therapy upon discharge as well as to earlier and more rigorous follow-up, according to Dr. Hanania. Although he cautioned that there is a meaningful risk of selection bias in a retrospective study, he thinks this study "is certainly probing an important issue."

"Mortality from a hospitalized COPD exacerbation exceeds that of a myocardial infarction," Dr. Hanania pointed out. Noting that all patients with an MI are evaluated by a cardiologist, he sees the logic of a pulmonologist consult – although he acknowledged that evidence is needed.

"I strongly believe that a prospective study is feasible and will answer the question in an unbiased manner if done properly," he said in an interview. If a multicenter, well-controlled study was positive, it could change practice.

In the event of a study showing major clinical benefits, particularly a reduction in mortality, "I believe it is feasible to have a pulmonary consult to see every COPD exacerbation patient admitted to the hospital," Dr. Hanania said.

Dr. Hekmat-Joo reports no relevant financial relationships. Dr. Hanania has financial relationships with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Novartis, Regeneron, Sanofi, and Sunovion.

2023 SIMULATION COURSES

CHEST Global Headquarters | Glenview, IL



Keep your knowledge and skill set up to date with our expert-led continuing medical education courses. Get all the relevant updates, plus the irreplaceable benefits of hands-on instruction and practice.



CHEST CURRICULUM PATHWAYS

CHEST's One-Stop Resource for Asthma Education

Expand your asthma knowledge with the CHEST Asthma Curriculum Pathway.

Access the best of CHEST asthma resources, including CHEST SEEK™ questions, podcasts, videos, and journal articles, in one easy-to-access destination.

Topics include pathophysiology, diagnosis and classification, management, and more.

- Access bite-sized learning
- Earn CME credit/MOC points
- Study on-the-go with the mobile app






CRITICAL CARE COMMENTARY Toward a healthy and sustainable critical care workforce in the COVID-19 era: A call for action

BY KELLY C. VRANAS, MD, AND MEETA PRASAD KERLIN, MD

he COVID-19 pandemic has caused unprecedented and unpredictable strain on health care systems worldwide, forcing rapid organizational modifications and innovations to ensure availability of critical care resources during acute surge events. Yet, while much attention has been paid to the availability of ICU beds and ventilators, COVID-19 has insidiously and

significantly harmed the most precious critical care resource of all – the human beings who are the lifeblood of critical care delivery. We are Dr. Vranas now at a crucial



moment in history to better understand the pandemic's impact on our human resources and enact changes to reverse the damage that it has inflicted on our workforce.

To understand the impact of the pandemic on critical care clinicians, we must first acknowledge the context in which they work. ICUs, where critical care delivery predominantly occurs, increasingly utilize interprofessional staffing models in which clinicians from multiple disciplines - physicians, nurses, clinical pharmacists, respiratory therapists, and dieticians, among others - bring their unique expertise to team-based clinical decisions and care delivery. Such a multidisciplinary approach helps enable the provision of more comprehensive, higher-quality critical care. In this way, the interprofessional ICU care team is an embodiment of the notion that the "whole" is more than just the sum of its parts. Therefore, we must consider the impact of the pandemic on interprofessional critical care clinicians as the team that they are.

Even before the COVID-19 pandemic, the well-being of critical care clinicians was compromised. Across multiple disciplines, they had among the highest rates of burnout syndrome of all health care professionals (Moss M, et al. Am J Respir Crit Care Med. 2016;194[1]:106-113). As the pandemic has dragged

on, their well-being has only further declined. Burnout rates are at all-time highs, and symptoms of posttraumatic stress disorder, anxiety, and depression are common and have increased with each subsequent surge (Azoulay E, et al. Chest. 2021;160[3]:944-955). Offsets to burnout, such as fulfillment and recognition, have declined over time (Kerlin MP, et al. Ann Amer Thorac Soc. 2022;19[2]:329-331). These worrisome trends pose a significant threat to critical care delivery. Clini-

cian burnout is associated with worse patient outcomes, increased medical errors, and lower patient satisfaction (Moss M, et al. Am J Respir

Crit Care Med. 2016;194[1]:106-113; Poghosyan L, et al. Res Nurs Health. 2010;33[4]:288-298). It is also associated with mental illness and substance use disorders among clinicians (Dyrbye LN, et al. Ann Intern Med. 2008;149[5]:334-341). Finally, it has contributed to a workforce crisis: nearly 500,000 health care workers have left the US health care sector since the beginning of the pandemic, and approximately two-thirds of acute and critical care nurses have considered doing so (Wong E. "Why Healthcare Workers are Quitting in Droves" https:// tinyurl.com/yaj5sde5. The Atlantic. Accessed November 7, 2022). Such a "brain drain" of clinicians - whose expertise cannot be easily replicated or replaced - represents a staffing crisis that threatens our ability to provide high-quality, safe care for the foreseeable future.

To combat burnout, it is first necessary to identify the mechanisms by which the pandemic has induced harm. Early during the pandemic, critical care clinicians feared for their own safety with little information of how the virus was spread. At a time when the world was under lockdown, vaccines were not yet available, and hospitals were overwhelmed with surges of critically ill patients, clinicians struggled like the rest of the world to meet their own basic needs such as childcare,

grocery shopping, and time with family. They experienced distress from high volumes of patients with extreme mortality rates, helplessness due to lack of treatment options, and moral injury over restrictive visitation policies (Vranas KC, et al. Chest. 2022;162[2]:331-345; Vranas KC, et al. Chest. 2021;160[5]:1714-1728). Over time, critical care clinicians have no doubt experienced further exhaustion related to the duration of the pandemic, often without adequate time to recover and process the trauma they have experienced. More recently, a new source of distress for clinicians has emerged from variability in vaccine uptake among the public. Clinicians have experienced compassion fatigue and even moral outrage toward those who chose not to receive a vaccine that is highly effective at preventing severe illness. They also suffered from ethical conflicts over how to treat unvaccinated patients and whether they should be given equal priority and access to limited therapies (Shaw D. Bioethics. 2022;36[8]:883-890).

Furthermore, the pandemic has damaged the relationship between clinicians and their institutions. Early in the pandemic, the widespread shortages of personal protective equipment harmed trust among clinicians due to their perception that their safety was not prioritized. Hospitals have also struggled with having to make rapid decisions on how to equitably allocate fixed resources in response to unanticipated and unpredictable demands, while also maintaining financial solvency. In some cases, these challenging policy decisions (eg, whether to continue elective procedures during acute surge events) lacked transparency and input from the team at the frontlines of patient care. As a result, clinicians have felt undervalued and without a voice in decisions that directly impact both the care they can provide their patients and their own well-being.

It is incumbent upon us now to take steps to repair the damage inflicted on our critical care workforce by the pandemic. To this end, there have been calls for the urgent implementation of strategies to mitigate the psychological burden experienced by critical care clinicians.

However, many of these focus on interventions to increase coping strategies and resilience among individual clinicians. While programs such as mindfulness apps and resilience training are valuable, they are not sufficient. The very nature of these solutions implies that the solution (and therefore, the problem) of burnout lies in the individual clinician. Yet, as described above, many of the mechanisms of harm to clinicians' well-being are systems-level issues that will necessarily require systems-level solutions.

Therefore, we propose a comprehensive, layered approach to begin to reverse the damage inflicted by the pandemic on critical care clinicians' well-being, with solutions organized by ecological levels of individual clinicians, departments, institutions, and society. With this approach, we hope to address specific aspects of our critical care delivery system that, taken together, will fortify the well-being of our critical care workforce as a whole. We offer suggestions below that are both informed by existing evidence, as well as our own opinions as intensivists and researchers.

At the level of the individual clinician:

- Proactively provide access to mental health resources. Clinicians have limited time or energy to navigate mental health and support services and find it helpful when others proactively reach out to them.
- Provide opportunities for clinicians to experience community and support among peers. Clinicians find benefit in town halls, debrief sessions, and peer support groups, particularly during times of acute strain.

At the level of the department:

• Allow more flexibility in work schedules. Even prior to the pandemic, the lack of scheduling flexibility and the number of consecutive days worked had been identified as key contributors to burnout; these have been exacerbated during times of caseload surges, when clinicians have been asked or even required to increase their hours and work extra shifts.

• Promote a culture of psychological safety in which clinicians feel empowered to say "I cannot work" for whatever reason. This will require the establishment of formalized backup systems that easily accommodate call-outs without relying on individual clinicians to find their own coverage.

At the level of the health care system:

- Prioritize transparency, and bring administrators and clinicians together for policy decisions. Break down silos between the frontline workers involved in direct patient care and hospital executives, both to inform those decisions and demonstrate the value of clinicians' perspectives.
- Compensate clinicians for extra work. Consider hazard pay or ensure extra time off for extra time worked.
- Make it "easier" for clinicians to do their jobs by helping them meet their basic needs. Create schedules with designated breaks during shifts. Provide adequate office space and call rooms. Facilitate access to childcare. Provide parking.
- Minimize moral injury. Develop protocols for scarce resource allocation that exclude the treatment team from making decisions about allocation of scarce resources. Avoid visitor restrictions given the harm these policies inflict on patients, families, and

members of the care team.

At the level of society:

• Study mechanisms to improve communication about public health with the public. Both science and communication are essential to promoting and protecting public health; more research is needed to improve the way scientific knowledge and evidence-based recommendations are communicated to the public.

In conclusion, the COVID-19 pandemic has forever changed our critical care workforce and the way we deliver care. The time is now to act on the lessons learned from the COVID-19 pandemic through implementation of systems-level solutions to combat burnout and ensure both the health and sustainability of our critical care workforce for the season ahead.

Dr. Vranas is with the Center to Improve Veteran Involvement in Care, VA Portland Health Care System, the Division of Pulmonary and Critical Care, Oregon Health & Science University; Portland, OR; and the Palliative and Advanced Illness Research (PAIR) Center, University of Pennsylvania; Philadelphia, PA. Dr. Kerlin is with the Palliative and Advanced Illness Research (PAIR) Center, and Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA.

This month in the journal CHEST®

Editor's picks

BY PETER J. MAZZONE, MD, MPH, FCCP Editor in Chief

Multidrug-Resistant and Extended-Spectrum Beta-Lactamase Gram-Negative Bacteria in Bilateral Lung Transplant Recipients: Incidence, Risk Factors, and In-Hospital Mortality. By Annalisa Boscolo, MD, PhD, et al.

Effectiveness of a Long-term Home-Based Exercise Training Program in Patients With COPD After Pulmonary Rehabilitation: A Multicenter Randomized Controlled Trial. By Anja Frei, PhD, et al.




COVID-19: Lessons Learned, Lessons Unlearned, Lessons for the Future. By Steven M. Hollenberg, ______ MD, et al.

> Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation. By Nicholas A. Bosch, MD, et al.

A Regional Command Center for Pandemic Surge. By Youcef Azeli, MD, PhD, et al.

Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension. *By Sheryl Wu, PharmD, et al.*





MORE

Honor Lectures & Annual Award Nominations

Recognize your colleague or mentor who is advancing chest medicine, providing mentorship and training, or furthering the mission of CHEST by nominating them for an honor lecture or annual award.



DONATE

NOW

CHEST 2023 Giveaway

Donate \$250 or more to the CHEST Foundation to be eligible. Donations made by December 31 will be entered in a drawing for:

- Two first-class airline tickets (US travel only)
- Hotel accommodations
- Complimentary CHEST 2023 registration

SCHEST[®]

Scenes from CHEST 2022

fter several long years of connecting via computer screens, the pulmonary, critical care, and sleep medicine community reunited in person Oct. 16-19 in Nashville for CHEST 2022. Attendees were welcomed back to a jam-packed schedule of more than 300 sessions full of the latest research and practicechanging updates, hands-on education mixed with entertainment, and opportunities to connect and collaborate.

CHEST 2022 brought back popular activities like the CHEST Challenge Championship and live gaming, and offered more than a few new options - including a rocking Opening Reception at the Wildhorse Saloon and opportunities for attendees to raise their voices on advocacy issues important to them. And that's just to name a few of the exciting




Annual meeting attendees show their CHEST pride with buttons and this year's free souvenir T-shirt.

elements that made this year's annual meeting a success.

Watch for the January issue of CHEST Physician for more CHEST 2022 coverage. Plus, mark your

calendar for CHEST 2023 in Hawaii, October 8-11. Learn more about CHEST 2023 at www.chestnet. org/Learning-and-Events/Events/ CHEST-Annual-Meeting.









Attendees at the Women & Pulmonary Luncheon hear career development advice from guest speaker Janet Bickel.

Opening Reception attendees brush up on their line-dancing skills at the Wildhorse Saloon.



Recipients of the prestigious Fellow of the American College of Chest Physicians designation are honored at the Opening Session.



Audience members at the CHEST Challenge Championship cheer on this year's competitors.

Following the CHEST Foundation in 2022

ince its inception in 1996, the CHEST Foundation has served patients and clinicians alike by supporting initiatives to educate, empower, and improve, but this may have been one of its most exciting and impactful years yet. As 2022 draws to a close, look back at the progress made over the past 12 months and the initiatives that will help the Foundation continue to support clinicians and patients in 2023.

Collaboration and communication key in 2022

2022 saw the launch of two new initiatives that will be integral to improving patient care in the years to come: The First 5 Minutes[™] and Bridging Specialties[™]: Timely Diagnosis for ILD Patients.

A collaborative partnership between CHEST and Three Lakes Foundation, Bridging Specialties

The CHEST Foundation continued to host engaging events throughout the year to encourage connection, raise awareness, and fundraise for important initiatives.

brings together pulmonologists and primary care physicians to define a clearer clinician-guided approach to diagnosis for ILDs like pulmonary fibrosis (PF).

A Steering Committee of multidisciplinary clinicians – including pulmonologists, primary care physicians, and a nurse practitioner – have led the development of important resources including a white paper highlighting the most recent data into delays in diagnosis.

Plus, a newly launched ILD Clinician Toolkit offers the following and more:

- An early detection learning module offering information about reasons for delayed ILD diagnosis, symptoms to watch and listen for (like crackles on auscultation), suggested patient workups, and recommendations on proactive steps to take, including when to refer to a pulmonologist;
- A decision-making tool offering interactive simulated patient visits; and
- Radiologic imaging videos covering key patterns, common CT

scan appearances and imaging features that can help in diagnosis of ILDs.

Clinicians can access the toolkit at bit.ly/Bridging-Specialties.

The First 5 Minutes

The First 5 Minutes initiative, developed in response to themes identified during the Foundation's Listening Tour in 2020, kicked off in Bexar County, TX, in June with an in-person pilot training program at the University of Texas Health Science Center.

There, relationship-centered communication trainers from the Academy of Communication Healthcare led 18 clinicians through interactive activities on empathetic listening and trust-building communication skills.

Attendees at CHEST 2022 had the opportunity to participate in a similar interactive session on Monday, October 17, where they practiced empathetic listening skills with fellow attendees and learned how establishing trust with patients in the first 5 minutes of interactions can lead to more efficient communication and improve patient adherence. Learn more at bit.ly/ First-5-Minutes.

CHEST gratefully acknowledges the following founding supporters of the First 5 Minutes[™]: Amgen, Astra-Zeneca, Bexar County, Novartis, Regeneron, Sanofi, and VIATRIS.

Making medicine a more inclusive practice

In February 2022, the American College of Chest Physicians (CHEST), the American Thoracic Society (ATS), and the American Lung Association announced a partnership with the prestigious Harold Amos Medical Faculty Development Program (AMFDP), a Robert Wood Johnson Foundation initiative, to sponsor a scholar in pulmonary and critical care medicine.

The recipient of that grant, George Alba, MD, Instructor of Medicine at Harvard Medical School and Pulmonary and Critical Care Physician at Massachusetts General, was announced earlier this year. Through his AMFDP award project, "Pulmonary Endothelial NEDD9 and Acute Lung Injury," Dr. Alba seeks to advance NEDD9 antagonism as a potential therapeutic target in acute respiratory distress syndrome (ARDS).

"Growing up, I saw through my

father's example how education unlocks opportunities. Our community came together to help him on this path. Now a retired doctor of osteopathy in neonatology, it inspired me to pursue a career in medicine," said Dr. Alba. "This award comes at a critical time in my junior faculty career: it allows me to continue pursuing my research in a meaningful way while also gaining new skills that will be critical for my ongoing career development."

Visit bit.ly/3X4VphB to learn

Twenty-five years of life-changing grants

In addition to all of this, the CHEST Foundation provides financial grants to advance medicine and support to those in need. More than 12 million dollars later, the CHEST Foundation is proud to bolster the field of medicine and enhance patient care through this support. Learn more about the impact of grants from recent recipients via the QR code here and in the September issue of CHEST Physician.



more about the AMFDP initiative

and Dr. Alba.

Fun and fellowship -

In addition, to all of this, the

CHEST Foundation continued to

host engaging events throughout

the year to encourage connection,

raise awareness, and fundraise for

This included the annual Belmont

FOUNDATION continued on following page

Stakes Dinner and Auction on June

11 in New York City. The fun-filled

for a good cause

important initiatives.

First 5 Minutes[™]

Minimal practice changes, major patient impact

Patients are more compliant and have better long-term outcomes when they feel understood. Build skills proven to lead to a positive relationship with your patients from the get-go with the new First 5 Minutes program.



Connect to resources that can make a difference in your practice.



CHEST gratefully acknowledges the following founding supporters of the First 5 Minutes™: Amgen, AstraZeneca, Bexar County, Novartis, Regeneron, Sanofi, and VIATRIS.

PULMONARY PERSPECTIVES® Race and spirometry

BY NICHOLAS E. GHIONNI, DO, AND CHRISTIAN J. WOODS, MD, FCCP

he European Respiratory Society (ERS) and American Thoracic Society (ATS) just published an update to their guidelines on lung function interpretation (Stanojevic S, et al. Eur Respir J. 2022; 60: 2101499). As with any update, the document builds on past work and integrates new advances the field has seen since 2005.

The current iteration comes at a time when academics, clinicians, and epidemiologists are re-analyzing what we think we know about the complex ways race and ethnicity intersect with the practice of medicine. Several experts on lung function testing, many if not most of whom are authors on the ERS/ ATS guideline, have written letters or published reviews commenting on the way accounting for race or ethnicity affects lung function interpretation.

Race/ethnicity and lung function was also the topic of an excellent session at the recent CHEST 2022 Annual Meeting in Nashville, Tennessee. Here, we'll provide a brief review and direct the reader to relevant sources for a more detailed analysis.

Spirometry is an integral part of the diagnosis and management of a wide range of pulmonary conditions. Dr. Aaron Baugh from the University of California San Francisco (UCSF) lectured on the spirometer's history at CHEST 2022 and detailed its interactions with race over the past 2 centuries. Other authors have chronicled this history, as well (Braun L, et al. Can J Respir Ther. 2015;51[4]:99-101). The short version is that since the British surgeon John Hutchinson created the first spirometer in 1846, race has been a part of the discussion of lung function interpretation.

In 2022, we know far more

about the factors that determine lung function than we did in the 19th century. Age, height, and sex assigned at birth all explain a high percentage of the variability seen in FEV1 and FVC. When modeled, race also explains a portion of the variability, and the NHANES III investigators found its inclusion in regression equations, along with age, height, and sex,

improved their precision. Case closed, right? Modern medicine is defined by phenotyping, precision, and individualized care, so why shouldn't race

be a part of lung function interpretation?

Well, it's complicated. With the increasing recognition of health disparities across racial groups the way race is incorporated in medical practice is understandably being scrutinized. As clinicians and academics, we must analyze the root cause of differences in health outcomes between racial groups.

Publications on pulse oximetry (Gottlieb ER, et al. JAMA Intern Med. 2022; 182:849-858) and glomerular filtration rate (Williams WW, et al. N Engl J Med. 2021;385:1804-1806) have revealed some of the ways our use of instruments and equations may exacerbate or perpetuate current disparities. Even small differences in a measure like pulse oximetry could have a profound impact on clinical decisions at the individual and population levels.

The 2022 ERS/ATS lung function interpretation guidelines have abandoned the use of NHANES III as a reference set. They now recommend the equations developed by the Global Lung Initiative (GLI) for referencing to normal for spirometry, diffusion capacity, and

lung volumes. For spirometry the GLI was able to integrate data from countries around the world. This allowed ethnicity to be included in their regression equations and, similar to NHANES III, they found ethnicity improved the precision of their equations. They also published an equation that did not account for country of origin that could be applied to individuals of any race/ethnicity (Quanjer PH, et al. Eur Respir J. 2014;43:505-512). This allowed for applying the GLI equations to external data sets with or without ethnicity included as a co-variate.

Given well-established discrepancies in spirometry, it should come as no surprise that applying the race/ ethnicity-neutral GLI As clinicians and equations to non-White populations academics, we must increases the percentage of patients with cause of differences pulmonary defects (Moffett AT, et al. in health outcomes Am J Respir Crit Care between racial groups. Med. 2021; A1030). Other data suggest that elimination

analyze the root

of race/ethnicity as a co-variate improves the association between percent predicted lung function and important outcomes like mortality (McCormack MC, et al. Am J Respir Crit Care Med. 2022;205:723-724). The first analysis implies that by adjusting for race/ethnicity we may be missing abnormalities, and the second suggests accuracy for outcomes is lost. So case closed, right? Let's abandon race/ethnicity as a covariate for our spirometry reference equations.

Perhaps, but a few caveats are in order. It's important to note that doing so would result in a dramatic increase in abnormal findings in otherwise healthy and asymptomatic non-White individuals. This could negatively affect eligibility for employment and military service

(Townsend MC, et al. Am J Respir Crit Care Med. 2022;789-790). We've also yet to fully explain the factors driving differences in lung function between races. If socioeconomic factors explained the entirety of the difference, it would be easier to argue for elimination of using race/ ethnicity in our equations. Currently, the etiology is thought to be multifactorial and is yet to be fully explained (Braun L, et al. Eur Respir J. 2013;41:1362-1370).

The more we look for institutional racism, the more we will find it. As we realize that attaining health and wellness is more difficult for the disenfranchised, we need to ensure our current practices are part of the

solution. The ERS/ATS guidelines suggest eliminating fixed correction factors for race but do not require elimination of race/ethnicity as a co-variate in the equations selected for use. This seems very reasonable given what we know now.

As pulmonary medicine academics and researchers, we need to continue to study the impact integrating race/ethnicity has on precision, accuracy, and clinical outcomes. As pulmonary medicine clinicians, we need to be aware of the reference equations being used in our lab, understand how inclusion of race/ ethnicity affects findings, and act accordingly, depending on the clinical situation.

Dr. Ghionni is a Pulmonary/Critical Care Fellow, and Dr. Woods is Program Director – PCCM Fellowship and Associate Program Director - IM Residency, Medstar Washington Hospital Center; Dr. Woods is Associate Professor of Medicine, Georgetown University School of Medicine, Washington, DC.

FOUNDATION continued from previous page

evening included a viewing of the 154th running of "The Championship Track," a cocktail reception and plated dinner, a silent auction, a rooftop party, and insights from two patient advocates who turned their own experiences of living with chronic lung disease into incredible action on behalf of patients.

Three virtual wine nights in April, August, and

December also invited numerous guests to learn more about imbibes from France, Italy, and California. Led by CHEST's own resident wine aficionado, CEO Bob Musacchio, PhD, these events benefited the AMFDP, as well as other initiatives to improve patient care.

2022 is special in another way. This year, the CHEST Foundation is offering an unmatched opportunity to one donor to attend CHEST 2023 in Honolulu, Hawai'i for free. For every \$250 you donate to the CHEST Foundation by December 31, 2022, you will receive an entry into a drawing for free registration, airfare (US only), and hotel accommodations.

Learn more about how you can donate to support initiatives like these - and make your mark on the practice of pulmonary, critical care, and sleep medicine – at foundation.chestnet.org.



Dr. Ghionni

12 • DECEMBER 2022 • CHEST PHYSICIAN

CARDIOLOGY Best anticoagulant for minimizing bleeding risk?

BY ROB HICKS, MBBS

commonly prescribed direct oral anticoagulant (DOAC) has the lowest risk of bleeding, say researchers. Used to prevent strokes in those with atrial fibrillation (AFib), DOACs have recently become more common than warfarin, the previous standard treatment, as they do not require as much follow-up monitoring - which was "particularly valuable" during the COVID-19 pandemic - and have "less risk" of side effects, highlighted the authors of a new study, published in Annals of Internal Medicine (2022 Nov 1. doi: 10.7326/ M22-0511).

However, the authors explained that, although current guidelines recommend using DOACs over warfarin in patients with AFib, "head-to-head trial data do not exist to guide the choice of DOAC." So, they set out to try and fill this evidence gap by doing a large-scale comparison between all DOACs – apixaban, dabigatran, edoxaban, and rivaroxaban – in routine clinical practice.

Wallis Lau, PhD, University College London, and co-lead author, said: "Direct oral anticoagulants have been prescribed with increasing frequency worldwide in recent years, but evidence comparing them directly has been limited."

One drug stood out

For the multinational population-based cohort study

the researchers compared the efficacy and risk of side effects for the four most common DOACs. They reviewed data - from five standardized electronic health care databases that covered 221 million people in the United Kingdom, France, Germany, and the United States of 527,226 patients who had been newly diagnosed with AFib between 2010 and 2019, and who had received a new DOAC prescription. The study included 281,320 apixaban users, 61,008 dabigatran users, 12,722 edoxaban users, and 172,176 rivaroxaban users.

Database-specific hazard ratios of ischemic stroke or systemic embolism, intracranial hemorrhage, gas-

"Apixaban stood out as having lower risk of gastrointestinal bleeding," said the authors, with a 19%-28% lower risk when compared directly with each of the other three DOACs.

trointestinal bleeding, and all-cause mortality between DOACs were estimated using a Cox regression model stratified by propensity score and pooled using a random-effects model.

In total, 9,530 ischemic stroke or systemic embolism events, 841 intercranial hemorrhage events, 8,319 gastrointestinal bleeding events, and 1,476 deaths were identified over the study follow-up. **Jonathan Ludmir, MD, FCCP, comments:** In my clinical practice, apixaban has consistently been my first choice of DOAC for patients with atrial fibrillation given its strong safety profile compared with warfarin. This retrospective review of the four main DOACs demonstrates a lower GI bleeding risk profile associated with apixaban. While this study seems to strengthen apixaban as a primary choice, it of course needs to be balanced with cost as well as the fact that it is a b.i.d. medication, often a challenge for patients.



The researchers found that all four drugs were comparable on outcomes for ischemic stroke, intercranial hemorrhage, and all-cause mortality.

However, they identified a difference in the risk of gastrointestinal bleeding, which they highlighted "is one of the most common and concerning side effects of DOACs."

"Apixaban stood out as having lower risk of gastrointestinal bleeding," said the authors, with a 19%-28% lower risk when compared directly with each of the other three DOACs. Specifically, apixaban use was associated with lower risk for gastrointestinal bleeding than use of dabigatran (HR, 0.81; 95% confidence interval, 0.70-0.94), edoxaban (HR, 0.77; 95% CI, 0.66-0.91), or rivaroxaban (HR, 0.72; 95% CI, 0.66-0.79).

The researchers highlighted that their findings held true when looking at data only from those older than 80, and those with chronic kidney disease, two groups that are "often underrepresented" in clinical trials.

Apixaban may be preferable

The researchers concluded that, among patients with AFib, apixaban use was associated with lower risk for GI bleeding and had similar rates of stroke or embolism, intracranial hemorrhage and all-cause mortality, compared with dabigatran, edoxaban, and rivaroxaban.

"Our results indicate that apixaban may be preferable to other blood thinners because of the lower rate of gastrointestinal bleeding and similar rates of stroke, a finding that we hope will be supported by randomized controlled trials," said Dr. Lau. However, he emphasized that, "as with all medications, potential risks and benefits can differ between people, so considering the full spectrum of outcomes and side effects will still be necessary for each individual patient."


The authors reported that they had no conflicts.

'A huge deal': Millions have long COVID, more expected

BY SOLARINA HO *MDedge News*

Roughly 7% of all adult Americans may currently have had long COVID, with symptoms that have lasted 3 months or longer, according to the latest U.S. government survey done in October. More than a quarter say their condition is severe enough to significantly limit their dayto-day activities – yet the problem is only barely starting to get the attention of employers, the health care system, and policymakers.

With no cure or treatment in sight, long COVID is already burdening not only the health care system, but also the economy – and that burden will grow. Many experts worry about possible longterm ripple effects, from increased spending on medical care costs to lost wages due to not being able to work, as well as the policy implications that



come with addressing these issues.

"At this point, anyone who's looking at this seriously would say this is a huge deal," said senior Brookings Institution fellow Katie Bach, the author of a study that analyzed long COVID's impact on the labor market. "We need a real concerted focus on treating these people, which means both research and the clinical side, and figuring out how to build a labor market that is more inclusive of people with disabilities," she said.

It's not only that many people are affected. It's that they are often affected for months and possibly even years.

The U.S. government figures suggest more than 18 million people could have symptoms of long COVID right now. The latest Household Pulse Survey by the Census Bureau and the National Center for Health Statistics takes data from 41,415 people. A preprint of a study by researchers from City University of New York, posted on medRxiv in September and based on a similar population survey done between June 30 and July 2, drew comparable results. The study has not

LONG COVID continued on following page

LONG COVID continued from previous page

been peer reviewed.

More than 7% of all those who answered said they had long COVID at the time of the survey, which the researchers said corresponded to approximately 18.5 million U.S. adults. The same study found that a quarter of those, or an estimated 4.7 million adults, said their daily activities were impacted "a lot."

This can translate into pain not only for the patients, but for governments and employers, too.

In high-income countries around the world, government surveys and other studies are shedding light on the extent to which post–COVID-19 symptoms – commonly known as long COVID – are affecting populations. While results vary, they generally fall within similar ranges.

The World Health Organization estimates that between 10%-20% of those with COVID-19 go on to have an array of medium- to long-term post-COVID-19 symptoms that range from mild to debilitating. The

Women appear almost twice as likely as men to get long COVID. Many patients have other medical conditions and disabilities that make them more vulnerable.

U.S. Government Accountability Office puts that estimate at 10% to 30%; one of the latest studies published at the end of October in The Journal of the American Medical Association found that 15% of U.S. adults who had tested positive for COVID-19 reported current long-COVID symptoms. Elsewhere, a study from the Netherlands published in The Lancet in August found that one in eight COVID-19 cases, or 12.7%, were likely to become long COVID.

"It's very clear that the condition is devastating people's lives and livelihoods," wrote WHO Director-General Tedros Adhanom Ghebreyesus in an article for The Guardian newspaper in October.

"The world has already lost a significant number of the workforce to illness, death, fatigue, unplanned retirement due to an increase in long-term disability, which not only impacts the health system, but is a hit to the overarching economy ... the impact of long COVID for all countries is very serious and needs immediate and sustained action equivalent to its scale."

Global snapshot:


Patients describe a spectrum of

persistent issues, with extreme fatigue, brain fog or cognitive problems, and shortness of breath among the most common complaints. Many also have manageable symptoms that worsen significantly after even mild physical or mental exertion.

Women appear almost twice as likely as men to get long COVID. Many patients have other medical conditions and disabilities that make them more vulnerable to the condition. Those who face greater obstacles accessing health care due to discrimination or socioeconomic inequity are at higher risk as well.

While many are older, a large number are also in their prime working age. The Census Bureau data show that people ages 40-49 are more likely than any other group to get long COVID, which has broader implications for labor markets and the global economy. Already, experts have estimated that long COVID is likely to cost the U.S. trillions of dollars and affect multiple industries.

"Whether they're in the financial world, the medical system, lawyers, they're telling me they're sitting at



ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

IMPORTANT SAFETY INFORMATION AND INDICATIONS WARNINGS AND PRECAUTIONS


Hepatic Impairment: OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dosage (100 mg twice daily). Consider treatment interruption or discontinuation for management of adverse reactions.

Elevated Liver Enzymes and Drug-Induced Liver Injury

- Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the clinical trials and postmarketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the post-marketing period. The majority of hepatic events occur within the first three months of treatment. OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases.
- In IPF studies, the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN.
- In the chronic fibrosing ILDs with a progressive phenotype study, the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin elevations had elevations less than 2 times ULN.
- In the SSc-ILD study, a maximum ALT and/or AST greater than or equal to 3 times ULN was observed in 4.9% of patients treated with OFEV.

the computer screen and they're unable to process the data," said Zachary Schwartz, MD, medical director for Vancouver General Hospital's Post-COVID-19 Recovery Clinic. "That is what's most distressing for people, in that they're not working, they're not making money, and they don't know when, or if, they're going to get better." Nearly a third of respondents in the Census Bureau's Household Pulse Survey who said they have had COVID-19 reported symptoms that lasted 3 months or longer. People between the ages of 30 and 59 were the most affected, with about 32% reporting symptoms. Across the entire adult U.S. population, the survey found that 1 in 7 adults have had long COVID at some point during the pandemic, with about 1 in 18 saying it limited their activity to some degree, and 1 in 50 saying they have faced "a lot" of limits on their activities. Any way these numbers are dissected, long COVID has impacted a large swath of the population. Yet research into the causes and possible treatments of long COVID is just getting underway.

"The amount of energy and time devoted to it is way, way less than it should be, given how many people are likely affected," said David Cutler, PhD, professor of economics at Harvard University, Cambridge, Mass. "We're way, way underdoing it LONG COVID continued on following page



See how the clinical trial data adds up at OFEVhcp.com/experience

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D) Elevated Liver Enzymes and Drug-Induced Liver Injury (cont'd)

- Elevated Liver Enzymes and Drug-Induced Liver Injury (cont'd)
- Patients with low body weight (less than 65 kg), patients who are Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may result in increased liver enzymes.
 Conduct liver function tests prior to initiation of treatment, at regular intervals during the first three months of
- treatment, and periodically thereafter or as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Dosage modifications, interruption, or discontinuation may be necessary for liver enzyme elevations.

Gastrointestinal Disorders Diarrhea

- Events were primarily mild to moderate in intensity and occurred within the first 3 months.
- In IPF studies, diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 11% and discontinuation
- in 5% of OFEV patients versus 0 and less than 1% in placebo patients, respectively.

Please see additional Important Safety Information on the following pages and accompanying Brief Summary of Prescribing Information.

LONG COVID continued from previous page

And I think that's really a terrible thing."

Population surveys and studies from around the world show that long COVID lives up to its name, with people reporting serious symptoms for months on end.

In October, Statistics Canada and the Public Health Agency of

Nearly three-quarters of workers or students who had long COVID said they missed an average of 20 days of work/school.

Canada published early results from a questionnaire done between spring and summer 2022 that found just under 15% of adults who had a confirmed or suspected case of COVID-19 went on to have new or continuing symptoms 3 or more months later. Nearly half, or 47.3%, dealt with symptoms that lasted a year or more. More than one in five said their symptoms "often or always" limited their day-to-day activities, which included tasks such as preparing meals, doing errands, chores, and basic functions such as personal care.

Nearly three-quarters of workers or students said they missed an

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D) Gastrointestinal Disorders (cont'd) Diarrhea (cont'd)

- In the chronic fibrosing ILDs with a progressive phenotype study, diarrhea was reported in 67% versus 24% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 16% and discontinuation in 6% of OFEV patients, compared to less than 1% of placebo-treated patients, respectively.
- In the SSc-ILD study, diarrhea was the most frequent gastrointestinal event reported in 76% versus 32% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 22% and discontinuation in 7% of OFEV patients versus 1% and 0.3% in placebo patients, respectively.
- Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider dose reduction or treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

Nausea and Vomiting

- In IPF studies, nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- In the chronic fibrosing ILDs with a progressive phenotype study, nausea was reported in 29% versus 9% and vomiting was reported in 18% versus 5% of patients treated with OFEV and placebo, respectively. Nausea led to discontinuation of OFEV in less than 1% of patients, and vomiting led to discontinuation of OFEV in 1% of the patients.
- In the SSc-ILD study, nausea was reported in 32% versus 14% and vomiting was reported in 25% versus 10% of patients treated with OFEV and placebo, respectively. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- In most patients, events were primarily of mild to moderate intensity. If nausea or vomiting persists despite appropriate supportive care including antiemetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

Embryo-Fetal Toxicity: OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use highly effective contraception at initiation of treatment, during treatment, and at least 3 months after the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptives containing ethinylestradiol and

levonorgestrel in patients with SSc-ILD. However, the efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. Verify pregnancy status prior to starting OFEV and during treatment as appropriate.

Arterial Thromboembolic Events

- In IPF studies, arterial thromboembolic events were reported in 2.5% of OFEV and less than 1% of placebo patients, respectively. Myocardial infarction (MI) was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and in less than 1% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, arterial thromboembolic events and MI were reported in less than 1% of patients in both treatment arms.
- In the SSc-ILD study, arterial thromboembolic events were reported in 0.7% of patients in both the OFEVtreated and placebo-treated patients. There were 0 cases of MI in OFEV-treated patients compared to 0.7% of placebo-treated patients.
- Use caution when treating patients at higher cardiovascular risk, including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Risk of Bleeding

- OFEV may increase the risk of bleeding.
- In IPF studies, bleeding events were reported in 10% of OFEV versus 7% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, bleeding events were reported in 11% of OFEV versus 13% of placebo patients.
- In the SSc-ILD study, bleeding events were reported in 11% of OFEV versus 8% of placebo patients.
- In clinical trials, epistaxis was the most frequent bleeding event. There have been post-marketing reports of non-serious and serious bleeding events, some of which were fatal. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk.

Gastrointestinal Perforation

- OFEV may increase the risk of gastrointestinal perforation.
- In IPF studies, gastrointestinal perforation was reported in less than 1% of OFEV versus in 0% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, gastrointestinal perforation was not reported in any treatment arm.
- In the SSc-ILD study, no cases of gastrointestinal perforation were reported in either OFEV or placebo-treated patients.

average of 20 days of work/school.

"We haven't yet been able to determine exactly when symptoms resolve," said Rainu Kaushal, MD, the senior associate dean for clinical research at Weill Cornell Medicine in New York. She is co-leading a national study on long COVID in adults and children, funded by the National Institutes of Health RECOVER Initiative. "But there does seem to be, for many of the milder symptoms, resolution at about 4-6 weeks. There seems to be a second point of resolution around 6 months for certain symptoms, and then some symptoms do seem to be permanent, and those tend to be patients who have underlying conditions," she said. Experts recommend urgent policy changes to help people with long COVID. "The population needs to be prepared, that understanding long COVID is going to be a very long and difficult process," said Alexander Charney, MD, PhD, associate professor and the lead principal investigator of the RECOVER adult cohort at Icahn School of Medicine at Mount Sinai in New York. He said the government can do a great deal, including setting up a network of connected clinics treating long COVID, standardizing best practices, and sharing information.

But the only known way to prevent long COVID is to prevent COVID-19 infections, experts say.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D) Gastrointestinal Perforation (cont'd)

 In the post-marketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, have a previous history of diverticular disease, or who are receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

Nephrotic Range Proteinuria: Cases of proteinuria within the nephrotic range have been reported in the postmarketing period. Histological findings, when available, were consistent with glomerular microangiopathy with or without renal thrombi. Improvement in proteinuria has been observed after OFEV was discontinued; however, in some cases, residual proteinuria persisted. Consider treatment interruption in patients who develop new or worsening proteinuria.

ADVERSE REACTIONS

Adverse Reactions observed in clinical trials were as follows:

Idiopathic Pulmonary Fibrosis

- The most common adverse reactions reported (greater than or equal to 5%) were diarrhea, nausea, abdominal pain, liver enzyme elevation, vomiting, decreased appetite, weight decreased, headache, and hypertension.
- The most frequent serious adverse reactions reported in patients treated with OFEV, more than placebo, were bronchitis (1.2% vs. 0.8%) and MI (1.5% vs. 0.4%). The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.

Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype

- The most common adverse reactions were consistent with those observed in IPF and also included nasopharyngitis, upper respiratory infection, urinary tract infection, fatigue and back pain.
- The most frequent serious adverse event reported in patients treated with OFEV, more than placebo, was pneumonia (4% vs. 3%). Adverse events leading to death were reported in 3% of OFEV patients and in 5% of placebo patients. No pattern was identified in the adverse events leading to death.

Systemic Sclerosis-Associated Interstitial Lung Disease

• The most common adverse reactions reported (greater than or equal to 5%) were diarrhea, nausea, vomiting, skin ulcer, abdominal pain, liver enzyme elevation, weight decreased, fatigue, decreased appetite, headache, pyrexia, back pain, dizziness, and hypertension.



Copyright ©2022, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (03/22) PC-US-121750A • The most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2.4% vs. 1.7%) and pneumonia (2.8% vs. 0.3%). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with placebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm.

DRUG INTERACTIONS

- P-glycoprotein (P-gp) and CYP3A4 Inhibitors
 - and Inducers: Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John's wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.
- **Anticoagulants:** Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

USE IN SPECIFIC POPULATIONS

- **Nursing Mothers:** Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment.
- **Reproductive Potential:** OFEV may reduce fertility in females of reproductive potential.
- **Smokers:** Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.

INDICATIONS

OFEV is indicated in adults for:

- Treatment of idiopathic pulmonary fibrosis (IPF).
- Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

CL-OF-100055 01.18.2022

Please see accompanying Brief Summary of Prescribing Information on the following pages.

References: 1. OFEV^{*} (nintedanib) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2022. **2.** Data on file. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. December 2020.



Repeat COVID infection doubles mortality risk

BY LISA O'MARY

etting COVID-19 a second time doubles a person's chance of dying and triples the likelihood of being hospitalized in the next 6 months, a new study found. Vaccination and booster status did not improve survival or hospitalization rates among people infected more than once.

"Reinfection with COVID-19

increases the risk of both acute outcomes and long COVID," author Ziyad Al-Aly, MD, told Reuters. "This was evident in unvaccinated, vaccinated, and boosted people." The study was published in the journal Nature Medicine (2022 Nov 10. doi: 10.1038/ s41591-022-02051-3).

Researchers analyzed U.S. Department of Veterans Affairs data, including 443,588 people with a first

OFEV[®] (nintedanib) capsules, for oral use BRIEF SUMMARY OF PRESCRIBING INFORMATION. Please see package insert for full Prescribing Information, including Patient Information

1 INDICATIONS AND USAGE: 1.1 Idiopathic Pulmonary Fibrosis: OFEV is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: OFEV is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. 1.3 Systemic Sclerosis-Associated Interstitial Lung Disease: OFEV is indicated to slow the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

2 DOSAGE AND ADMINISTRATION: 2.1 Testing Prior to OFEV Administration: Conduct i/2.1 lesting Prior to OFEV Administration: Conduct i/2.1 lesting Prior ductive potential prior to initiating treatment with OFEV *[see Warnings and Precautions]*. **2.2 Recommended Dosage:** The recommended dosage of OFEV is 150 mg taken orally twice daily administered approximately 12 heuro paget. Administration Information; DEV approximately 12 hours apart. Administration Information: OFEV capsules should be taken with food and swallowed whole with liquid. OFEV capsules should not be chewed or crushed because of a bitter taste. OFEV capsules should not be opened or crushed. If contact with the content of the capsule occurs, wash hands immediately and thoroughly. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known. Information for Missed Dose: If a dose of OFEV is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of exceed the recommended maximum daily dosage of 300 mg. 2.3 Recommended Dosage for Patients with Hepatic Impairment: Mild Hepatic Impairment: In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of OFEV is 100 mg orally twice daily approximately 12 hours apart taken with food [see Use in Specific Populations]. Moderate or Severe Hepatic Impairment: Treatment with OFEV is not rec-ommended [see Warnings and Precautions and Use in Specific Populations]. 2.4 Dosage Modification due to Adverse Beactions: In addition to symptomatic treat-Adverse Fleations: In addition to symptomatic treat-ment, if applicable, the management of adverse reac-tions of OFEV may require dose reduction or temporary tions of OFEV may require dose reduction of temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatmost with OEEV [ace Warning and Precenting) treatment with OFEV [see Warnings and Precautions and Adverse Reactions]. Elevated Liver Enzymes: Dose modifications or interruptions may be necessary for liver enzyme elevations. Conduct liver function tests (aspar-tate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin) prior to initiation of treatment with OFEV, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Discontinue OFEV in patients with AST or ALT greater than 3 times the upper limit of normal (ULN) with signs or symptoms of liver injury and for AST OLLY will signs of symptoms of niver injury and on AST or ALT elevations greater than 5 times the upper limit of normal. For AST or ALT greater than 3 times to less than 5 times the ULN without signs of liver damage, inter-rupt treatment or reduce OFEV to 100 mg twice daily. Once liver enzymes have returned to baseline values, treatment with OFEV may be reintroduced at a reduced decage (100 mg twice daily, which subsequently may dosage (100 mg twice daily), which subsequently may be increased to the full dosage (150 mg twice daily) [see Warnings and Precautions and Adverse Reactions]. In patients with mild hepatic impairment (Child Pugh A) consider treatment interruption, or discontinuation for management of adverse reactions.

4 CONTRAINDICATIONS: None

5 WARNINGS AND PRECAUTIONS: 5.1 Hepatic Impairment: Treatment with OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment [*see Use in Specific Populations*]. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dose of OFEV [*see Dosage and Administration*]. **5.2 Elevated Liver Enzymes and Drug-Induced Liver Injury:**

Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the clinical trials and postmarketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the postmarketing period. The majority of hepatic events occur within the first three months of treatment. In clinical trials, administration of OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification (Studies 1, 2, and 3), the majority of cases. In IPF studies (Studies 1, 2, and 3), the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with biliru bin elevations had elevations less than 2 times ULN. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin ele-ULN and the majority (94%) of patients with bilirubin ele-vations had elevations less than 2 times ULN. In the SSc-ILD study (Study 4), a maximum ALT and/or AST greater than or equal to 3 times ULN was observed for 4.9% of patients in the OFEV group and for 0.7% of patients in the placebo group [*see Use in Specific Populations*]. Patients with a low body weight (less than 65 kg), Asian, and female patients may have a higher risk of elevations in liver enzymes. Conduct liver function tests (ALT, AST, and bilirubin) prior to initiation of treatment with OFEV, at reg-ular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. and periodically thereafter or as clinically indicated. Measure liver tests promptly in patients who report symp-toms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Dosage modifications or interruption may be necessary for liver enzyme elevations. [see Dosage and Administration]. **5.3 Gastrointestinal Disorders:** <u>Diarrhea</u>: In clinical trials, diarrhea was the most frequent gastrointestinal event reported. In most patients, the event was of mild to moderate intensity and occurred within the first 3 months of treatment. In IPF studies (Studies 1, 2, and 3), diarrhea was reported in 62% versus 18% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. Diarrhea led to permanent dose reduction in 11% of patients treated with OFEV compared to 0 placebo-treated patients. Diarrhea led to discontinu-ation of OFEV in 5% of the patients compared to less than 1% of placebo-treated patients. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), diar-rhea was reported in 67% versus 24% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. Diarrhea led to permanent dose reduction in 16% of patients treated with OFEV compared to less than 1% of placebo-treated patients. Diarrhea led to discontinuation of OFEV in 6% of the patients compared to less than 1% of placebo-treated patients. In the SSc-ILD study (Study 4), diarrhea was reported in 76% versus 32% of patients treated with OFEV and placebo, respec-tively *[see Adverse Reactions]*. Diarrhea led to permanent dose reduction in 22% of patients treated with OFEV compared to 1% of placebo-treated patients. Diarrhea led to discontinuation of OFEV in 7% of the patients compared to 0.3% of placebo-treated patients. Dosage mod ifications or treatment interruptions may be necessary in patients with adverse reactions of diarrhea. Treat diarrhea at first signs with adequate hydration and antidiar rheal medication (e.g., loperamide), and consider treat-ment interruption if diarrhea continues [see Dosage and Administration]. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists despite symptomatic treatment, discontinue treatment with OFEV. <u>Nausea and Vomiting</u>: In IPF studies (Studies With OFEV. <u>Natused and Vollming</u>: In IPF studies (studies 1, 2, and 3), nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), nausea was reported in 29% versus 9% and vomiting was reported in 18% versus 5% of patients treated with OFEV and placebo respectively. In the SSCtreated with OFEV and placebo, respectively. In the SSc-ILD study (Study 4), nausea was reported in 32% versus 14% and vomiting was reported in 25% versus 10% of patients treated with OFEV and placebo, respectively *[see Adverse Reactions]*. In most patients, these events were of mild to moderate intensity. In IPF studies (Studies 1, 2, and 3), nausea led to discontinuation of OFEV in 2% of patients and vomiting led to discontinuation of OFEV in 2% of 1% of the patients. In the chronic fibrosing ILDs with a

progressive phenotype study (Study 5), nausea led to dis-continuation of OFEV in less than 1% of patients and vomiting led to discontinuation of OFEV in 1% of the patients. In the SSc-ILD study (Study 4), nausea led to discontinuation of OFEV in 2% of patients and vomiting led to discontinuation of OFEV in 1% of the patients. For nausea or vomiting that persists despite appropriate support-ine care including artic amount deep and using on the study of the patients. The second secon does not resolve, discontinue treatment with OFFV. 5.4 **Embryo-Fetal Toxicity:** Based on findings from animal studies and its mechanism of action, OFEV can cause fetal harm when administered to a pregnant woman. Nintedanib caused embryo-fetal deaths and structural abnormalities in rats and rabbits when administered during organogenesis at less than (rats) and approxi-mately 5 times (rabbits) the maximum recommended human dose (MRHD) in adults. Advise pregnant women of the potential risk to a fetus. Advise females of reproduc-tive potential to avoid becoming pregnant while receiving treatment with OFEV and to use highly effective contraception at initiation of, during treatment, and at least 3 months after the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptive containing ethinylestradiol and levonorgestrel in patients with SSc-ILD. However, the efficacy of oral hormonal contra-ceptives may be compromised by vomiting and/or diarhear or other conditions where the drug absorption may be reduced. Advise women taking oral hormonal contra-ceptives experiencing these conditions to use alternative highly effective contraception. Verify pregnancy status prior to treatment with OFEV and during treatment as appropriate [see Use in Specific Populations]. **5.5** Arterial Thromboembolic Events: Arterial thromboem bolic events have been reported in patients taking OFEV. In IPF studies (Studies 1, 2, and 3), arterial thromboembolic vents were reported in 2.5% of patients treated with OFEV and 0.8% of placebo-treated patients. Myocardial infarction was the most common adverse reaction under arterial thromboembolic events, occurring in 1.5% of OFEV-treated patients compared to 0.4% of place-bo-treated patients. In the chronic fibrosing ILDs with a bo-treated patients. In the chronic horosing ILUs with a progressive phenotype study (Study 5), arterial thrombo-embolic events were reported in less than 1% of patients in both treatment arms. Myocardial infarction was observed in less than 1% of patients in both treatment arms. In the SSc-ILD study (Study 4), arterial thromboem-bolic events were reported in 0.7% of patients in both treatment arms. There are a foregoing of patients in both treatment arms. There were 0 cases of myocardial infar-tion in OFEV-treated patients compared to 0.7% of place-bo-treated patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischwhile develop signs or symptoms of actue inforcation inscri-emia. 5.6 Risk of Bleeding: Based on the mechanism of action (VEGRF inhibition), OFEV may increase the risk of bleeding. In IPF studies (Studies 1, 2, and 3), bleeding events were reported in 10% of patients treated with OFEV and in 7% of patients treated with placebo. In the blacking in the with events are blacking about the state blacking. chronic fibrosing ILDs with a progressive phenotype study (Study 5), bleeding events were reported in 11% of patients treated with OFEV and in 13% of patients treated with placebo. In the SSc-ILD study (Study 4), bleeding events were reported in 11% of patients treated with OFEV and in 8% of patients treated with placebo. In the perturbating pacido pape sprivue and sprivue bleeding postmarketing period non-serious and serious bleeding events, some of which were fatal, have been observed. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. 5.7 **Gastrointestinal Perforation:** Based on the mechanism of action, OFEV may increase the risk of gastrointestinal perforation. In IPF studies (Studies 1, 2, and 3), gastrointestinal perforation was reported in 0.3% of patients treated with OFEV, compared to 0 cases in the place between device larger and the place between the place betw patients treated with UFEV, compared to 0 cases in the placebo-treated patients. In the chronic fibrosing LDs with a progressive phenotype study (Study 5), gastroin-testinal perforation was not reported in any patients in any treatment arm. In the SSc-ILD study (Study 4), no cases of gastrointestinal perforation were reported in patients treated with OFEV or in placebo-treated patients. In the potemarkating paried cases of gastrointestinal In the postmarketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or

infection of SARS-CoV-2, 40,947 people who were infected two or more times, and 5.3 million people who had not been infected and whose data served as a control.

"During the past few months, there's been an air of invincibility among people who have had COVID-19 or their vaccinations and boosters, and especially among

NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk. 5.8 Nephrotic Range Proteinuria: Cases of proteinuria within the nephrotic range have been reported in the postmarketing period. Histological findings, when available, were consistent with glomerular microangiopathy with or without renal thrombi. Improvement in protein-uria has been observed after OFEV was discontinued; however, in some cases, residual proteinuria persisted Consider treatment interruption in patients who develop new or worsening proteinuria.

6 ADVERSE REACTIONS: The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Elevated Liver Enzymes and Drug-Induced Liver Injury [see Warnings and Precautions]; Gastrointestinal Disorders [see Warnings and Precautions]; Embryo-Fetal Toxicity [see Warnings and Precautions]; Finity of lear to Active See Warnings and Precautions]; Arterial Thromboembolic Events [see Warnings and Precautions]; Risk of Bleeding [see Warnings and Precautions]; Gastrointestinal Perforation [see Warnings and Precautions]; Nephrotic Range Proteinuria [see Warnings and Precautions]. 6.1 Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reac-tion rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates of served in practice. The safety of OFEV was evaluated in over 1000 IPF patients, 332 patients with chronic fibrosing ILDs with a progres-sive phenotype, and over 280 patients with SSc-ILD. Over 200 IPF patients were exposed to OFEV for more than 200 IPF p 2 years in clinical trials. <u>Idiopathic Pulmonary Fibrosis</u>: OFEV was studied in three randomized, double-blind, placebo-controlled, 52-week trials. In the phase 2 (Study 1) and phase 3 (Studies 2 and 3) trials, 723 patients with IPF received OFEV 150 mg twice daily and 508 patients particulations for provide the phase 2 (Study received placebo. The median duration of exposure was 10 months for patients treated with OFEV and 11 months for patients treated with DFEV and 11 months for patients treated with placebo. Subjects ranged in age from 42 to 89 years (median age of 67 years). Most patients were male (79%) and Caucasian (60%). The most frequent serious adverse reactions reported in patients treated with DFEV expected and the placebox were breakting (40 were 0.0%). OFEV, more than placebo, were bronchitis (1.2% vs. 0.8%) and myocardial infarction (1.5% vs. 0.4%). The most com mon adverse events leading to death in patients treated with OFEV, more than placebo, were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined ategory of major adverse cardiovascular events (MACE including MI, fatal events were reported in 0.6% of OFEV-treated patients and 1.8% of placebo-treated patients Adverse reactions leading to permanent dose reductions were reported in 16% of OFEV-treated patients and 1% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (11%). Adverse reactions leading to discontinuation were reported in 21% of OFEV treated patients and 15% of placebo-treated patients. The most frequent adverse reactions that led to discontinuation in OFEV-treated patients were diarrhea (5%), nausea (2%) and decreased appetite (2%). The most common adverse reactions with an incidence of greater than or equal to 5% and more frequent in the OFEV than placebo treatment group are listed in Table 1.

people who have had an infection and also received vaccines; some people started to [refer] to these individuals as having a sort of superimmunity to the virus," Dr. Al-Aly said in a press release from Washington University in St. Louis. "Without ambiguity, our research showed that getting an infection a second, third, or fourth time

contributes to additional health risks in the acute phase, meaning the first 30 days after infection, and in the months beyond, meaning the long COVID phase."

Being infected with COVID-19 more than once also dramatically increased the risk of developing lung problems, heart conditions, or brain conditions. The heightened

risks persisted for 6 months.

The Veterans Affairs population does not reflect the general population and they are generally older with more than normal health complications, said John Moore, PhD, a professor of microbiology and immunology at Weill Cornell Medicine, New York. Dr. Moore was not involved in the study.

Adverse Reactions Occurring in \geq 5% of **OFEV-treated Patients with Idiopathic** Pulmonary Fibrosis and More Commonly Than Placebo in Study 1, Study 2, and Study 3

Adverse Reaction	OFEV,	Placebo
	150 mg	n=508
	n=723	
Gastrointestinal disorders		
Diarrhea	62%	18%
Nausea	24%	7%
Abdominal pain ^a	15%	6%
Vomiting	12%	3%
Hepatobiliary disorders		
Liver enzyme elevation ^b	14%	3%
Metabolism and nutrition		
disorders		
Decreased appetite	11%	5%
Nervous system		
disorders		
Headache	8%	5%
Investigations		
Weight decreased	10%	3%
Vascular disorders		

Hypertension 5% 4% Includes abdominal pain, abdominal pain upper, abdominal pair lower, gastrointestinal pain and abdominal tenderness. Includes gamma-glutamyltransferase increased, hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic function abnormal, liver function test abnormal, transaminase increased, blood alkaline phosphatase-increased, alanine aminotrans ferase abnormal, aspartate aminotransferase abnormal, and gamma-glutamyltransferase abnormal. Includes hypertension, blood pressure increased, hypertensive

crisis, and hypertensive cardiomyopathy

In addition, hypothyroidism was reported in patients treated with OFEV, more than placebo (1.1% vs. 0.6%). <u>Combination with Pirfenidone</u>: Concomitant treatment with nintedanib and pirfenidone was investigated in an exploratory open-label, randomized (1:1) trial of nintedanib 150 mg twice daily with add-on pirfenidone (titrated to 801 mg three times a day) compared to nintedanib 150 mg twice daily alone in 105 randomized patients for 12 weeks. The primary endpoint was the percentage of patients with gastrointestinal adverse events from baseline to Week 12. gastrointestinal adverse events from baseline to week 12. Gastrointestinal adverse events were in line with the established safety profile of each component and were experienced in 37 (70%) patients treated with pirfenidone added to nintedanib versus 27 (53%) patients treated with nintedanib alone. Diarrhea, nausea, vomiting, and addominal pain (includes upper abdominal pain, abdominal discomfort, and abdominal pain) were the most frequent adverse events reported in 20 (38%) versus 16 (31%), in 22 (42%) versus 6 (12%), in 15 (28%) versus 6 (12%) patients, and in 15 (28%) versus 7 (14%) treated with pirfenidone added to nintedanib versus nintedanib alone respectively. More subjects reported AST or ALT elevations (greater than or equal to 3x the upper limit of normal) (greater than of equal to 5x the upper limit of hormal) when using pirfenidone in combination with nintedanib (n=3 (6%)) compared to nintedanib alone (n=0) [see Warnings and Precautions]. Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: OFEV was studied in a phase 3, double-blind, placebo-controlled trial (Study 5) in which 663 patients with chronic fibrosing ILDs with a progressive phenotype upper patients and the proving with a progressive phenotype were randomized to receive OFEV 150 mg twice daily (n=332) or placebo (n=331) for at least 52 weeks. At 52 weeks, the median duration of exposure was 12 months for patients in both freatment arms. Subjects ranged in age from 27 to 87 years (median age of 67 years). The majority of patients were Caucasian (74%) or Asian (25%). Most patients were male (54%). The most frequent serious adverse event reported in patients treated with OFEV, more than placebo, was pneumonia (4% vs. 3%). Adverse events leading to death were reported in 3% of patients treated with OFEV and in 5% of patients treated with placebo. No pattern was identified in the adverse events leading to death. Adverse reactions leading to permanent dose reductions were reported in 33% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reaction that led to OFEV was diarrhea (16%). Adverse reactions leading to discontinuation were reported in 20% of OFEV-treated patients and 10% of placebo-treated patients. The most

frequent adverse reaction that led to discontinuation in OFEV-treated patients was diarrhea (6%). The safety pro-file in patients with chronic fibrosing ILDs with a progres-sive phenotype treated with OFEV was consistent with that observed in IPF patients. In addition, the following adverse Doserved in PEP patients. In addition, the following adverse events were reported in OFEV more than placebo in chronic progressive fibrosing ILD: nasopharyngitis (13% vs. 12%), upper respiratory tract infection (7% vs. 6%), urinary tract infection (6% vs. 4%), fatigue (10% vs. 6%), and back pain (6% vs. 5%). <u>Systemic Sclerosis-Associated Interstitial Lung Disease</u>: OFEV was studied in a phase 3, merdeniated dauble blind, placebe constrailed that field (Studied Interstitial Lung). Automatic European Controlled trial (Study 4) in which 576 patients with SSc-ILD received OFEV 150 mg twice daily (n=288) or placebo (n=288). Patients TSU mg twice daily (n=288) or placebo (n=288). Patients were to receive treatment for at least 52 weeks; individual patients were treated for up to 100 weeks. The median duration of exposure was 15 months for patients treated with OFEV and 16 months for patients treated with placebo. Subjects ranged in age from 20 to 79 years (median age of 55 years). Most patients were female (75%). Patients were mostly Caucasian (67%). Asian (25%). Patients were mostly Caucasian (67%), Asian (25%), or Black (6%). At baseline, 49% of patients were on stable therapy with mycophenolate. The most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2.4% nintedanib vs 1.7% placebo) and pneumonia (2.8% nin-tedanib vs 0.3% placebo). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with pla-cebo (1.4%) died. There was no pattern among adverse Cebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm. Adverse reactions leading to permanent dose reductions were reported in 34% of OFEV-treated patients and 4% of pla-cebo-treated patients. The most frequent adverse reac-tion that led to permanent dose reduction in the patients treated with OFEV was diarrhea (22%). Adverse reactions leading to discontinuation were reported in 16% of OFEV-treated patients and 9% of placebo-treated patients. The most frequent adverse reactions that led to discontinuamost frequent adverse reactions that led to discontinua-tion in OFEV-treated patients were diarrhea (7%), nausea (2%), vomiting (1%), abdominal pain (1%), and intersti-tial lung disease (1%). The safety profile in patients with or without mycophenolate at baseline was comparable. The most common adverse reactions with an incidence of greater than or equal to 5% in OFEV-treated patients and most ecomponent then in plenche are listed in Teble 0. and more commonly than in placebo are listed in Table 2. Table 2 Adverse Reactions Occurring in >5%

of OFEV-treated Patients with Systemic Sclerosis-Associated Interstitial Lung Disease and More Commonly Than Placebo in Study 4

Adverse Reaction	0FEV, 150 mg n=288	Placebo n=288
Diarrhea	76%	32%
Nausea	32%	14%
Vomiting	25%	10%
Skin ulcer	18%	17%
Abdominal pain ^a	18%	11%
Liver enzyme elevation ^b	13%	3%
Weight decreased	12%	4%
Fatigue	11%	7%
Decreased appetite	9%	4%
Headache	9%	8%
Pyrexia	6%	5%
Back pain	6%	4%
Dizziness	6%	4%
Hypertension ^c	5%	2%

lower, and esophageal pain. Includes alanine aminotransferase increased, gamma-glutamyltransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, blood alkaline

phosphatase increased, transaminase increased, and hepatic function abnormal

Includes hypertension, blood pressure increased, and

hypertensive crisis

6.2 Postmarketing Experience: The following adverse reactions have been identified during postapproval use of OFEV. Because these reactions are reported use of UFEV. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during postapproval use of OFEV: drug-induced liver injury [see Warnings and Precautions], non-serious and serious bloading evonts come of which wore fatal bleeding events, some of which were fatal

PULMONOLOGY

CDC warns of early uptick in respiratory disease

BY LUCY HICKS

MDedge News

he Centers for Disease Control and Prevention is warning of an early surge in respiratory disease caused by multiple viruses. As influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2, and rhinovirus/enterovirus simultaneously circulate, the CDC cautioned that this confluence of viral activity could strain the health care system, according to a Nov. 4 CDC Health Network Alert advisory.

"This early increase in disease incidence highlights the importance of optimizing respiratory virus

[see Warnings and Precautions], proteinuria [see Warnings and Precautions], pancreatitis, thrombocytopenia, rash, pruritus.

7 DRUG INTERACTIONS: 7.1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers: Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4. Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV *[see Dosage and Administration]*. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducer, carbamazepine, phenytoin, and St. John's wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib. **7.2 Anticoagulants**: Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary [*see Warnings and Precautions*]. **7.3 Pirfenidone**: In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone. **7.4 Bosentan:** Coadministration of nintedanib with bosentan did not alter the pharmacokinetics of nintedanib.

8 USE IN SPECIFIC POPULATIONS: 8.1 Pregnancy: Risk Summary: Based on findings from animal studies and ts mechanism of action, OFEV can cause fetal harm when administered to a pregnant woman. There are no data on the use of OFEV during pregnancy. In animal studies of pregnant rats and rabbits treated during organogenesis, nintedanib caused embryo-fetal deaths and structural abnormalities at less than (rats) and approximately 5 times (rabbits) the maximum recommended human dose [see Data]. Advise pregnant women of the poten-tial risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and miscarriage in clinically recognized pregnancies is 15% to 20%. <u>Data</u>: *Animal Data*: In animal reproduction toxicity studies, nintedanib caused embryo-fetal deaths and structural abnormalities in rats and rabbits at less than and approximately 5 times the maximum recommended human dose (MRHD) in adults (on a plasma AUC basis at maternal oral doses of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). Malformations included abnormalities in the vasculature, urogenital, and skeletal systems. Vasculature anomalies included missing or additional major blood vessels. Skeletal anoma-Ing of additional major blood vessels. Skeletal ahoma-lies included abnormalities in the thoracic, lumbar, and caudal vertebrae (e.g., hemivertebra, missing, or asym-metrically ossified), ribs (bifid or fused), and sternebrae (fused, split, or unilaterally ossified). In some fetuses, organs in the urogenital system were missing. In rabbits, a significant change in sex ratio was observed in fetuses (female:male ratio of approximately 71%:29%) at approx-imately 15 times the MRHD in adults (on an AUC basis at a maternal oral dose of 60 mg/kg/day). Nintedanib decreased post-natal viability of rat pups during the first 4 post-natal days when dams were exposed to less than the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day). **8.2 Lactation:** <u>Risk Summary</u>: There is no information on the presence of nintedanib in human milk, the effects on the breast-fed infant or the effects on milk production. Nintedanib and/or its metabolites are present in the milk of lactating rats [see Data]. Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment with OFEV. <u>Data</u>: Wilk and plasma of lactating rats have similar concen-trations of nintedanib and its metabolites. **8.3 Females** and Males of Reproductive Potential: Based on findings from animal studies and its mechanism of action, OFEV can cause fetal harm when administered to a pregnant woman and may reduce fertility in females of reproductive potential *(see Use in Specific Populations)*. Coursel patients on pregnancy prevention and plan-ning. <u>Pregnancy Testing</u>: Verify the pregnancy status of females of reproductive potential prior to treatment

with OFEV and during treatment as appropriate. [see Dosage and Administration, Warnings and Precautions and Use in Specific Populations]. <u>Contraception</u>: OFEV can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to avoid becoming pregnant while receiving treatment with OFEV. Advise females of reproductive potential to use highly effective contraception at initiation of, during treatment, and for at least 3 months after taking the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptive containing ethinylestradiol and levonorge-strel in patients with SSc-ILD. However, the efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where the drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. Infertility: Based on animal data, OFEV may reduce fertility in females of reproductive potential. **8.4 Pediatric Use:** Safety and effectiveness in pediatric patients have not been established **8.5 Geriatric Use:** Of the total number of subjects in phase 2 and 3 clinical studies of OFEV in IPF. 60.8% were 65 and over, while 16.3% were 75 and IPF, 60.8% Were 65 and over, while 7.8% were 75 and over. In the chronic fibrosing ILDs with a progressive phe-notype clinical study (Study 5), 61% were 65 and over, while 19% were 75 and older. In SSc-ILD, 21.4% were 65 and over, while 1.9% were 75 and older. In phase 3 studies, no overall differences in effectiveness were observed between subjects who were 65 and over and younger subjects; no overall differences in safety were observed between subjects who were 65 and over or 75 and over and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. **8.6 Hepatic** Impairment: Nintedanib is predominantly eliminated via billary/fecal excretion (greater than 90%). In a PK study performed in patients with hepatic impairment (Child Pugh A, Child Pugh B), exposure to nintedanib was increased. In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of OFEV is 100 mg twice daily [see Dosage and Administration]. Monitor for adverse reactions and consider treatment interruption, or discontinuation for management of adverse reac-tions in these patients *[see Dosage and Administration]*. Treatment of patients with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment with OFEV is not recommended [see Warnings and Precautions]. 8.7 Renal Impairment: Based on a single-dose study less than 1% of the total dose of nintedanib is excreted via the kidney. Adjustment of the starting dose in patients with mild to moderate renal impairment is not required. The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (less than 30 mL/min CrCl) and end-stage renal disease. **8.8 Smokers:** Smoking was associated with decreased exposure to OFEV, which may alter the efficacy profile of OFEV. Encourage patients to stop smoking prior to treat-ment with OFEV and to avoid smoking when using OFEV.

10 OVERDOSAGE: In IPF trials, one patient was inadvertently exposed to a dose of 600 mg daily for a total of 21 days. A non-serious adverse event (nasopharyngitis) occurred and resolved during the period of incorrect dosing, with no onset of other reported events. Overdosage was also reported in two patients in oncology studies who were exposed to a maximum of 600 mg twice daily for up to 8 days. Adverse events reported were consistent with the existing safety profile of OFEV. Both patients recovered. In case of overdosage, interrupt treatment and initiate general supportive measures as appropriate.

17 PATIENT COUNSELING INFORMATION: Advise the patient to read the FDA-approved patient labeling (Patient Information). Elevated Liver Enzymes and Drug-Induced Liver Injury: Advise patients that they will need to undergo liver function testing periodically. Advise patients to immediately report any symptoms of a liver problem (e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleed or bruise more easily than normal, lethargy, loss of appetite) [see Warnings and Precautions]. <u>Gastrointestinal Disorders</u>: Inform patients that gastrointestinal disorders such as diarrhea, nausea, and voniting were the most commonly reported gastrointestinal events occurring in patients who received OFEV. Advise patients that their healthcare provider may recommend hydration, antidiarrheal medications (e.g., loperamide), or anti-emetic medications to treat these side effects. Temporary dosage reductions or toreat their healthcare provider at the first signs of diarrhea or for any severe or persistent diarrhea,

nausea, or vomiting [see Warnings and Precautions and Adverse Reactions]. Embryo-Fetal Toxicity: Counsel Adverse Reactions]. Embryo-Fetal Toxicity: Counsel patients on pregnancy prevention and planning. Advise emales of reproductive potential of the potential risk to a fetus and to avoid becoming pregnant while receiving treatment with OFEV. Advise females of reproductive potential to use highly effective contraception at initiation of, during treatment, and for at least 3 months after taking the last dose of OFEV. Advise women taking oral hormona contraceptives who experience vomiting and/or diar rhea or other conditions where the drug absorption may be reduced to contact their doctor to discuss alternative highly effective contraception. Advise female patients to notify their doctor if they become oregnant or suspect they are pregnant during therapy with OFEV [see Warnings and Precautions and Use in Specific Populations]. Arterial Thromboembolic Events: Advise patients about the signs and symptoms of acute myocardial ischemia and other arterial thromboembolic vents and the urgency to seek immediate medical care for these conditions *[see Warnings and Precautions]*. <u>Risk</u> of <u>Bleeding</u>: Bleeding events have been reported. Advise patients to report unusual bleeding [see Warnings and Precautions]. <u>Gastrointestinal Perforation</u>: Serious gastro-intestinal perforation events have been reported. Advise patients to report signs and symptoms of gastrointestinal perforation [see Warnings and Precautions]. <u>Nephrotic</u> <u>Range Proteinuria</u>: Nephrotic range proteinuria has been reported. Advise patients to report signs and symptoms of proteinuria (e.g., fluid retention, foamy urine) [see Warnings and Precautions]. <u>Lactation</u>: Advise proteint that breastfoading is not reported urine) [see Warnings and rrecautors]. Lauration, Advise patients that breastfeeding is not recommended while taking OFEV [see Use in Specific Populations]. Smokers: Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using OFEV. <u>Administration</u>: Instruct patients to take using OFEV. <u>Administration</u>: Instruct patients to take OFEV with food, to swallow OFEV capsules whole with liquid and not to chew or crush the capsules due to the bitter taste. Advise patients or caregivers not to open or crush OFEV capsules and to wash hands immediately and thoroughly if contact with the content of the capsule occurs. Advise patients to not make up for a missed dose [see Dosage and Administration].

Copyright © 2022 Boehringer Ingelheim International GmbH ALL RIGHTS RESERVED

COL9114BA132022 (02/22)

) Boehringer Ingelheim

CL-0E-100064

prevention and treatment measures, including prompt vaccination and antiviral treatment," the alert stated.

The CDC reports that RSV activity is increasing nationally, but in some areas – such as the South and Mountain West – cases appear to be trending downward.

Influenza cases continue to climb, with the virus activity being the highest in the South, Mid-Atlantic, and the south-central West Coast, according to CDC data. "In fact, we're seeing the highest influenza hospitalization rates going back a decade," said José Romero, MD, director of the CDC's National Center for Immunization and Respiratory Diseases, during a press briefing. The agency estimates that there have been 1.6 million illnesses, 13,000 hospitalizations, and 730 deaths from the flu so far this season. As of Nov. 4, there have been two pediatric deaths.

COVID-19 cases appear to have plateaued in the past 3 weeks, Dr. Romero said; however, the CDC expects that there will be "high-level circulation of SARS-CoV-2 this fall and winter," the health alert stated.

The CDC advised that all eligible individuals aged 6 months or older should be vaccinated against COVID-19 and influenza. To protect against RSV-hospitalization, high-risk children should receive the monoclonal antibody drug palivizumab (Synagis). High-risk children include infants born before 29 weeks, children younger than age 2 with chronic lung disease or hemodynamically significant congenital heart disease, and children with suppressed immune systems or neuromuscular disorders.

Any patient with confirmed or suspected flu who is hospitalized, at higher risk for influenza complications, or who has a severe or progressive illness should be treated as early as possible with antivirals, such as oral oseltamivir (Tamiflu).

Patients with confirmed SARS-CoV-2 infection with increased risk of complications should also be treated with antivirals, such as nirmatrelvir and ritonavir (Paxlovid) or remdesivir (Veklury).

"There's no doubt that we will face some challenges this winter," said Dawn O'Connell, HHS Assistant Secretary for Preparedness and Response.

"But it's important to remember that RSV and flu are not new, and we have safe and effective vaccines for COVID-19 and the flu."

Race and gender: Tailoring treatment for sleep

BY WALTER ALEXANDER *MDedge News*

FROM CHEST 2022 • While trials of various interventions for obstructive sleep apnea and insomnia were effective, there was a strong suggestion that tailoring them according to the race/gender of the target populations strengthens engagement and improvements, according to a presentation by Dayna A. Johnson, PhD, MPH, at the annual meeting of the American College of Chest Physicians (CHEST).

Dr. Johnson, assistant professor at Emory University in Atlanta, stated that determinants of sleep disparities are multifactorial across the lifespan, from in utero to aging, but it was also important to focus on social determinants of poor sleep.

The complexity of factors, she said, calls for multilevel interventions beyond screening and treatment. Racism and discrimination come into play, especially with regard to anxiety and stress, In addition, neighborhood factors including safety, noise and light pollution, ventilation, and thermal comfort come into play, affecting sleep.

Dr. Johnson cited the example of parents who work multiple jobs to provide for their families: "Minimum wage is not a livable wage, and parents may not be available to ensure that children have consistent bedtimes." Interventions, she added, may have to be at the neighborhood level, including placing sleep specialists in the local neighborhood "where the need is." Cleaning up a neighborhood reduces crime and overall health, while light shielding in public housing can lower light pollution.

Observing that African Americans have higher rates of obstructive sleep apnea, Dr. Johnson and colleagues designed a screening tool specifically for African Americans **Brandon M. Seay, MD, comments:** This article not only argues that tailoring treatment to a patient's race and gender can lead to better diagnosis and treatment of sleep disorders, but provides data to back it up. This is crucially important to remember in sleep medicine. Sleep disorders can affect almost every organ system in the body; therefore treating these disorders can have a huge impact on patients. We can't have cookiecutter approaches to our patients when tailored approaches can have such a huge effect.



with five prediction models with increasing levels of factor measurements (from 4 to 10). The prediction accuracy across the models ascended in lockstep with the number of measures from 74.0% to 76.1%, with the simplest model including only age, body mass index, male sex, and snoring. The latter model added witnessed apneas, high depressive symptoms, two measures of waist and neck size, and sleepiness. Dr. Johnson pointed out that accuracy for well-established predictive models is notably lower: STOP-Bang score ranges from 56% to 66%; NoSAS ranges from 58% to 66%, and the HCHS prediction model accuracy is 70%. Dr. Johnson said that a Latino model they developed was more accurate than the traditional models, but not as accurate as their model for African Americans.

Turning to specific interventions, and underscoring higher levels of stress and anxiety among African American and Hispanic populations, Dr. Johnson cited MINDS (Mindfulness Intervention to Improve Sleep and Reduce Diabetes Risk Among a Diverse Sample in Atlanta), her study at Emory University of mindfulness meditation. Although prior studies have confirmed sleep benefits of mindfulness meditation, studies tailored for African American or Hispanic populations have been lacking.

The MINDS pilot study investigators enrolled 17 individuals (mostly women, with a mixture of racial and ethnic groups comprising Black, White, Asian, and Hispanic patients) with poor sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI). Most patients, Dr. Johnson said, were overweight. Because of COVID restrictions on clinic visits, the diabetes portion of the study was dropped. All participants received at least 3 days of instruction on mindfulness meditation, on dealing with stress and anxiety, and on optimum sleep health practices. While PSQI scores higher than 5 are considered to indicate poor sleep quality, the mean PSQI score at study outset in MINDS was 9.2, she stated.

After 30 days of the intervention, stress (on a perceived stress scale) was improved, as were PSQI scores and actigraphy measures of sleep duration, efficiency and wakefulness after sleep onset, Dr. Johnson reported. "Participants found the mindfulness app to be acceptable and appropriate, and to reduce time to falling asleep," Dr. Johnson said.

Qualitative data gathered post intervention from four focus groups (two to six participants in each; 1-1.5 hours in length), revealed general acceptability of the MINDS app. It showed also that, among those with 50% or more adherence to the intervention, time to falling asleep was reduced, as were sleep awakenings at night. The most striking finding, Dr. Johnson said, was that individuals from among racial/ethnic minorities expressed appreciation of the diversity of the meditation instructors, and said that they preferred instruction from a person of their own race and sex. Findings would be even more striking with a larger sample size, Dr. Johnson speculated.

Citing TASHE (Tailored Approach to Sleep Health Education), a further observational study on obstructive sleep apnea knowledge conducted at New York University, Dr. Johnson addressed the fact that current messages are not tailored to racial and/ or ethnic minorities with low-tomoderate symptom knowledge. Also, a 3-arm randomized clinical trial of Internet-delivered treatment (Sleep Healthy or SHUTI) with a version revised for Black women (SHUTI-BWHS) showed findings similar to those of other studies cited and suggested: "Tailoring may be necessary to increase uptake and sustainability and to improve sleep among racial/ ethnic minorities."

Dr. Johnson noted, in closing, that Black/African American individuals have higher risk for obstructive sleep apnea than that of their White counterparts and lower rates of screening for treatment.

Dr. Johnson's research was funded by the National Institutes of Health; National Heart, Lung, and Blood Institute; Woodruff Health Sciences Center; Synergy Award; Rollins School of Public Health Dean's Pilot and Innovation Award; and Georgia Center for Diabetes Translation Research Pilot and Feasibility award program. She reported no relevant conflicts.

Achieving diversity, equity, and inclusion: Invite everyone

BY WALTER ALEXANDER

MDedge News

FROM CHEST 2022 What you really don't want to do, if you want to improve diversity, equity, and inclusion (DEI) at your academic institution, is to recruit diverse people to your program and then have them come and feel not included, said Vivian Asare, MD. "That can work against your efforts," she stated in an oral presentation at the annual meeting of the American College of Chest Physicians (CHEST). Dr. Asare is assistant

professor and vice chief of DEI for Yale Pulmonary, Critical Care, and Sleep Medicine, and associate medical director of Yale Centers for Sleep Medicine, New Haven, Conn.

In offering a path to successful DEI, Dr. Asare said: "The first step is to build a team and discuss your mission. Invite everyone to participate and include your leadership because they're the ones who set the stage, ensure sustainability, and can be a liaison with faculty." Then a DEI leader should be elected, she added.

The next and very important step is to survey

the current institutional climate. "You need to tap into how people feel about DEI in your program." That entails speaking directly with the stakeholders (faculty, staff, trainees) and identifying their specific concerns and what they think is lacking. Retreats, serious group discussions, and self-reflecting (asking "what initiatives would be good for us?"), and meeting one-on-one with individuals for a truly personalized approach are among potentially productive strategies for identifying the priorities and DIVERSITY continued on following page

MDEDGE.COM/CHESTPHYSICIAN • DECEMBER 2022 • 21

When you support CHEST's philanthropic efforts, you join forces with other individuals committed to expanding their impact on lung disease and chest medicine. You will fund programs that change how people live, receive treatment, and enjoy an improved quality of life.





Champion lung health today by making your year-end donation.

Big or small, your donation matters. The CHEST Foundation thanks you for your continued support and we wish you and yours a happy, healthy holiday season.





DIVERSITY continued from previous page

DEI-related topics specific to a particular academic sleep program.

Dr. Asare offered up a sample DEI survey (Am J Obstet Gynecol. 2020 Nov;223[5]:715.e1-715.e7), that made direct statements inviting the respondent to check off one of the following responses: Yes, No, Somewhat, Do not know, and Not applicable. Among sample statements:

- Our department is actively committed to issues of diversity, equity, and inclusion.
- Faculty searches in the department regularly attract a diverse pool of highly qualified candidates and/or attract a pool that represents the availability of MDs in this field.
- Our outreach and recruitment processes employ targeted practices for attracting diverse populations.

Dr. Asare said that a survey can be a simple approach for garnering information that can be useful for prioritizing DEI topics of concern and igniting interest in them. Engagement requires regular DEI committee meetings with minutes or a newsletter and with updates and topics brought to faculty meetings.

Key DEI areas of focus

Dr. Asare listed several key DEI areas: recruitment/retention, mentorship, scholarship, and inclusion and community engagement. Under scholarship, for example, she cited topics for potential inclusion in a DEI curriculum: unconscious bias and anti-racism training, racism, discrimination and microaggression education (bystander/ deescalation training), cultural competency and awareness, workplace civility, and health disparities. "We all know that implicit bias in providers is a reality, unfortunately," Dr. Asare said. Being aware of these implicit biases is a start, but instruction on how to actively overcome them has to be provided. Tools may include perspectivetaking, exploring common identity, and self-reflection.

To create an inclusive environment for all faculty, trainees, and staff may involve establishing a "welcome committee" for new fac-

"The first step is to build a team and discuss your mission. Invite everyone to participate and include your leadership because they're the ones who set the stage, ensure sustainability, and can be a liaison with faculty."

ulty, perhaps with designating a "peer buddy," creating social events and other opportunities for all opinions and ideas to be heard and valued. Particularly for underserved and disadvantaged patient populations, patient advocacy and community service need to be fostered through support groups and provision of resources.

Summarizing, Dr. Asare reiterated several key elements for a successful DEI program: Build a team and discuss the mission, survey the current climate allowing open communication and dialogue, plan and engage, organize, and form areas of DEI focus. Find out where you are and where you want to be with respect to DEI, she concluded.

Dr. Asare declared that she had no conflicts of interest.

PULMONOLOGY Iron deficiency may protect against bacterial pneumonia

BY HEIDI SPLETE MDedge News

FROM CHEST 2022
Patients with iron deficiency anemia who developed bacterial pneumonia showed improved outcomes compared to those without iron deficiency anemia, based on data from more than 450,000 individuals in the National Inpatient Sample.

Iron deficiency is the most common nutritional deficiency worldwide, and can lead to anemia, but iron also has been identified as essential to the survival and growth of pathogenic organisms, Mubarak

"Should you consider a delay in treatment [of iron deficiency anemia] if the patient is not symptomatic?"

Yusuf, MD, said in a presentation at the annual meeting of the American College of Chest Physicians (CHEST).

However, the specific impact of iron deficiency anemia (IDA) on outcomes in patients hospitalized with acute bacterial infections has not been explored, said Dr. Yusuf, a third-year internal medicine

resident at Lincoln Medical Center in New York.

In the study, Dr. Yusuf and colleagues reviewed data from the Nationwide Inpatient Sample (NIS) Database for 2016-2019. They identified 452,040 adults aged 18 or older with a primary diagnosis of bacterial pneumonia based on ICD-10 codes. Patients with a principal diagnosis other than bacterial pneumonia were excluded.

Of these, 5.5% had a secondary diagnosis of IDA. The mean age of the study population was similar between the IDA and non-IDA groups (68 years) and racial distribution was similar, with a White majority of approximately 77%. Slightly more patients in the IDA group were women (58.5% vs. 51.6%) and this difference was statistically significant (P < .00001). Most of the patients (94.6%) in the IDA group had at least three comorbidities, as did 78.1% of the non-IDA group.

The primary outcome was mortality, and the overall mortality in the study population was 2.89%. Although the mortality percentage was higher in the IDA group compared to the non-IDA group (3.25% vs. 2.87%), "when we adjusted for confounders, we noticed a decreased odds of mortality in the IDA group" with an adjusted odds ratio of 0.74 (P = .001), Dr. Yusuf said.

David L. Bowton, MD, FCCP, comments: The study by Yusef and colleages is a fascinating analysis of the National Inpatient Sample examining the link between iron deficiency anemia (IDA) and outcomes from sepsis. Their data suggest that patients with IDA had a lower mortality than those without IDA. Iron is an essen-

tial nutrient for both bacteria and humans. The mechanisms by which this might occur remain speculative. Many bacteria require iron for their pathogenicity, while excess iron has been linked to oxidative injury and can trigger cell death. Humans have evolved an extraordinary system for both storing and sequestering iron to enable its availability for essential processes while minimizing the potential adverse consequences of unnecessary iron availability.



Importantly, as with all studies involving admin-

istrative data, the criteria for the diagnosis of either IDA or sepsis are not known. A recent meta-analysis found an increased risk of infection in patients receiving intravenous iron (for a variety of indications), but without an apparent increase in mortality (Shah AA, et al. JAMA Network Open. 2021;4(11):e2133935). The acute treatment of IDA with intravenous iron prior to major abdominal surgery did not reduce transfusion requirements nor have an impact on mortality (Richards T, et al. Lancet. 2020;396(10259):1353-1361). Collectively, I believe the available evidence suggests we should be cautious in the administration of iron to acutely ill patients.

In addition, secondary outcomes of septic shock, acute respiratory failure, and cardiac arrest were lower in the IDA group in a regression analysis, with adjusted odds ratios of 0.71, 0.78, and 0.57, respectively.

The mean length of stay was 0.3 days higher in the IDA group, and the researchers found a nonsignificant increase in total hospital costs of \$402.5 for IDA patients compared to those without IDA, said Dr. Yusuf.

The take-home message from the study is actually a question to the clinician, Dr. Yusuf said. "Should you consider a delay in treatment [of iron deficiency anemia] if the patient is not symptomatic?" he asked.

More research is needed to investigate the improved outcomes in the iron deficient population, but the large sample size supports an association that is worth exploring, he concluded.

"The findings of this research may suggest a protective effect of iron deficiency in acute bacterial pneumonia," Dr. Yusuf said in a press release accompanying the meeting presentation. "More research is needed to elucidate the improved



outcomes found in this population, but this research may lead clinicians to consider a delay in treatment of nonsymptomatic iron deficiency in acute bacterial infection," he added.

The study received no outside funding. The researchers had no financial conflicts to disclose.

Bridging Specialties™: Timely Diagnosis for ILD Patients

Bridging Specialties: Timely Diagnosis for ILD Patients brings together pulmonologists and primary care physicians to define a clearer clinician-guided approach to diagnosis for ILDs.

Early diagnosis for ILDs is essential. Time is of the essence in diagnosing ILDs but the signs can be difficult to recognize.



If you hear this, it might be ILD

A common symptom of ILD is a crackle on auscultation. It's important to listen at the bottom of the lungs, as this is where the crackles are most commonly heard.



Hear what crackles can sound like.



THREE LAKES FOUNDATION

EXAMPLES CHEST Physician®



Find important updates and features from *CHEST Physician*[®] in one web resource:

MDedge.com/CHESTPhysician

NEWS FROM THE FIELD AND CHEST[®]



CONFERENCE COVERAGE



EXPERT PERSPECTIVES



HEALTH POLICY, TECH, AND COSTS OF CARE



FEATURES, JOURNAL COVERAGE, AND MORE

